Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,17959330,flow rate,"Analyses were performed on an Agilent 1100 Series HPLC system employing a Supelco Ascentis C(18) column and isocratic elution with acetonitrile-10mM ammonium acetate buffer pH 4.0 (30:70, v/v) at a flow rate of 0.25 mL/min.",Development and validation of a LC-MS method with electrospray ionization for the determination of the imidazole H3 antagonist ROS203 in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959330/),[ml] / [min],0.25,6213,DB00747,Scopolamine
,17959330,retention times,"The retention times of ROS203 and IS were 2.20 and 2.90 min, respectively.",Development and validation of a LC-MS method with electrospray ionization for the determination of the imidazole H3 antagonist ROS203 in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959330/),min,2.20,6214,DB00747,Scopolamine
,17959330,retention times,"The retention times of ROS203 and IS were 2.20 and 2.90 min, respectively.",Development and validation of a LC-MS method with electrospray ionization for the determination of the imidazole H3 antagonist ROS203 in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959330/),min,2.90,6215,DB00747,Scopolamine
,30822710,IC50,"Among these derivatives, compound 9b exhibited the highest ability to block H3R (IC50 = 0.27 μM) and good inhibitory activity against AChE (IC50 = 0.08 μM).","Design, synthesis, and evaluation of isoflavone analogs as multifunctional agents for the treatment of Alzheimer's disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30822710/),μM,0.27,7566,DB00747,Scopolamine
,30822710,IC50,"Among these derivatives, compound 9b exhibited the highest ability to block H3R (IC50 = 0.27 μM) and good inhibitory activity against AChE (IC50 = 0.08 μM).","Design, synthesis, and evaluation of isoflavone analogs as multifunctional agents for the treatment of Alzheimer's disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30822710/),μM,0.08,7567,DB00747,Scopolamine
,30822710,log BB,"Moreover, in vivo data revealed that compound 9b did not cause acute toxicity in mice at doses up to 1000 mg/kg, and had desirable pharmacokinetic properties, as well as a good blood-brain barrier (BBB) permeability (log BB = 1.24 ± 0.07).","Design, synthesis, and evaluation of isoflavone analogs as multifunctional agents for the treatment of Alzheimer's disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30822710/),,1.24,7568,DB00747,Scopolamine
,24748278,maximum drug plasma concentrations (C max),"After i.v. administration, the maximum drug plasma concentrations (C max) of Atr, Ani, AT3, and Sco were 274.25 ± 53.66, 267.50 ± 33.16, 340.50 ± 44.52, and 483.75 ± 78.13 ng/mL.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),[ng] / [ml],274.25,9682,DB00747,Scopolamine
,24748278,maximum drug plasma concentrations (C max),"After i.v. administration, the maximum drug plasma concentrations (C max) of Atr, Ani, AT3, and Sco were 274.25 ± 53.66, 267.50 ± 33.16, 340.50 ± 44.52, and 483.75 ± 78.13 ng/mL.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),[ng] / [ml],267.50,9683,DB00747,Scopolamine
,24748278,maximum drug plasma concentrations (C max),"After i.v. administration, the maximum drug plasma concentrations (C max) of Atr, Ani, AT3, and Sco were 274.25 ± 53.66, 267.50 ± 33.16, 340.50 ± 44.52, and 483.75 ± 78.13 ng/mL.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),[ng] / [ml],340.50,9684,DB00747,Scopolamine
,24748278,maximum drug plasma concentrations (C max),"After i.v. administration, the maximum drug plasma concentrations (C max) of Atr, Ani, AT3, and Sco were 274.25 ± 53.66, 267.50 ± 33.16, 340.50 ± 44.52, and 483.75 ± 78.13 ng/mL.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),[ng] / [ml],483.75,9685,DB00747,Scopolamine
,24748278,bioavailability,"Because of their partial solubility, Atr, Ani, AT3, and Sco had different bioavailability in rats of 21.62, 10.78, 80.45 and 2.52 %, respectively.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),%,21.62,9686,DB00747,Scopolamine
,24748278,bioavailability,"Because of their partial solubility, Atr, Ani, AT3, and Sco had different bioavailability in rats of 21.62, 10.78, 80.45 and 2.52 %, respectively.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),%,10.78,9687,DB00747,Scopolamine
,24748278,bioavailability,"Because of their partial solubility, Atr, Ani, AT3, and Sco had different bioavailability in rats of 21.62, 10.78, 80.45 and 2.52 %, respectively.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),%,80.45,9688,DB00747,Scopolamine
,24748278,bioavailability,"Because of their partial solubility, Atr, Ani, AT3, and Sco had different bioavailability in rats of 21.62, 10.78, 80.45 and 2.52 %, respectively.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),%,2.52,9689,DB00747,Scopolamine
below,24748278,C max,"Following i.g. administration of tiotropium, the C max value below 20 ng/mL revealed the very low oral absorption.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),[ng] / [ml],20,9690,DB00747,Scopolamine
,24748278,urinary excretion rates,"The urinary excretion rates of Atr, Ani, AT3, Sco and tiotropium were 11.33, 54.86, 32.67, 8.69 and 73.91 %.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),%,11.33,9691,DB00747,Scopolamine
,24748278,urinary excretion rates,"The urinary excretion rates of Atr, Ani, AT3, Sco and tiotropium were 11.33, 54.86, 32.67, 8.69 and 73.91 %.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),%,54.86,9692,DB00747,Scopolamine
,24748278,urinary excretion rates,"The urinary excretion rates of Atr, Ani, AT3, Sco and tiotropium were 11.33, 54.86, 32.67, 8.69 and 73.91 %.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),%,32.67,9693,DB00747,Scopolamine
,24748278,urinary excretion rates,"The urinary excretion rates of Atr, Ani, AT3, Sco and tiotropium were 11.33, 54.86, 32.67, 8.69 and 73.91 %.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),%,8.69,9694,DB00747,Scopolamine
,24748278,urinary excretion rates,"The urinary excretion rates of Atr, Ani, AT3, Sco and tiotropium were 11.33, 54.86, 32.67, 8.69 and 73.91 %.","Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24748278/),%,73.91,9695,DB00747,Scopolamine
,27373949,flow rate,"Separation was achieved on C18 column using a mobile phase consisting methanol-water (70:30, v/v) at a flow rate of 1.0ml/min.","Pharmacokinetics and pharmacodynamics of a novel Acetylcholinesterase Inhibitor, DMNG-3. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27373949/),[ml] / [min],1.0,10300,DB00747,Scopolamine
,27373949,absolute recovery,The mean absolute recovery of DMNG-3 in plasma ranged from 88.55 to 96.45 %.,"Pharmacokinetics and pharmacodynamics of a novel Acetylcholinesterase Inhibitor, DMNG-3. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27373949/),%,88.55 to 96.45,10301,DB00747,Scopolamine
,27373949,elimination half-life (T1/2),"The elimination half-life (T1/2) was 14.07±1.29, 15.87±1.03h, and the total clearance (CL) values were 0.70±0.11, 0.78±0.13 L/h/kg, respectively.","Pharmacokinetics and pharmacodynamics of a novel Acetylcholinesterase Inhibitor, DMNG-3. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27373949/),h,14.07,10302,DB00747,Scopolamine
,27373949,elimination half-life (T1/2),"The elimination half-life (T1/2) was 14.07±1.29, 15.87±1.03h, and the total clearance (CL) values were 0.70±0.11, 0.78±0.13 L/h/kg, respectively.","Pharmacokinetics and pharmacodynamics of a novel Acetylcholinesterase Inhibitor, DMNG-3. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27373949/),h,15.87,10303,DB00747,Scopolamine
,27373949,total clearance (CL),"The elimination half-life (T1/2) was 14.07±1.29, 15.87±1.03h, and the total clearance (CL) values were 0.70±0.11, 0.78±0.13 L/h/kg, respectively.","Pharmacokinetics and pharmacodynamics of a novel Acetylcholinesterase Inhibitor, DMNG-3. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27373949/),[l] / [h·kg],0.70,10304,DB00747,Scopolamine
,27373949,total clearance (CL),"The elimination half-life (T1/2) was 14.07±1.29, 15.87±1.03h, and the total clearance (CL) values were 0.70±0.11, 0.78±0.13 L/h/kg, respectively.","Pharmacokinetics and pharmacodynamics of a novel Acetylcholinesterase Inhibitor, DMNG-3. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27373949/),[l] / [h·kg],0.78,10305,DB00747,Scopolamine
,9542560,peak plasma concentrations,The peak plasma concentrations of scopolamine after deltoid or gluteal injection (2.2 vs 1.6 micrograms/l) and the time they were reached (17 vs 19 min) were comparable.,Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),[μg] / [l],2.2,15230,DB00747,Scopolamine
,9542560,peak plasma concentrations,The peak plasma concentrations of scopolamine after deltoid or gluteal injection (2.2 vs 1.6 micrograms/l) and the time they were reached (17 vs 19 min) were comparable.,Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),[μg] / [l],1.6,15231,DB00747,Scopolamine
,9542560,time,The peak plasma concentrations of scopolamine after deltoid or gluteal injection (2.2 vs 1.6 micrograms/l) and the time they were reached (17 vs 19 min) were comparable.,Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),min,17,15232,DB00747,Scopolamine
,9542560,time,The peak plasma concentrations of scopolamine after deltoid or gluteal injection (2.2 vs 1.6 micrograms/l) and the time they were reached (17 vs 19 min) were comparable.,Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),min,19,15233,DB00747,Scopolamine
,9542560,Tmax,"The absorption of morphine was similar in both groups (Tmax 16 min), but the peak plasma concentrations were higher after deltoid injection (71 vs 49 micrograms/l).",Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),min,16,15234,DB00747,Scopolamine
,9542560,peak plasma concentrations,"The absorption of morphine was similar in both groups (Tmax 16 min), but the peak plasma concentrations were higher after deltoid injection (71 vs 49 micrograms/l).",Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),[μg] / [l],71,15235,DB00747,Scopolamine
,9542560,peak plasma concentrations,"The absorption of morphine was similar in both groups (Tmax 16 min), but the peak plasma concentrations were higher after deltoid injection (71 vs 49 micrograms/l).",Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),[μg] / [l],49,15236,DB00747,Scopolamine
,9542560,T1/2,"The individual variation in the elimination half-lives of both scopolamine and morphine was smaller after deltoid injection (T1/2 scopolamine 1.9 +/- 0.7 vs 2.1 +/- 1.1 h, morphine 1.3 +/- 0.7 vs 2.3 +/- 1.5 h).",Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),h,1.9,15237,DB00747,Scopolamine
,9542560,T1/2,"The individual variation in the elimination half-lives of both scopolamine and morphine was smaller after deltoid injection (T1/2 scopolamine 1.9 +/- 0.7 vs 2.1 +/- 1.1 h, morphine 1.3 +/- 0.7 vs 2.3 +/- 1.5 h).",Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),h,2.1,15238,DB00747,Scopolamine
,9542560,T1/2,"The individual variation in the elimination half-lives of both scopolamine and morphine was smaller after deltoid injection (T1/2 scopolamine 1.9 +/- 0.7 vs 2.1 +/- 1.1 h, morphine 1.3 +/- 0.7 vs 2.3 +/- 1.5 h).",Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),h,1.3,15239,DB00747,Scopolamine
,9542560,T1/2,"The individual variation in the elimination half-lives of both scopolamine and morphine was smaller after deltoid injection (T1/2 scopolamine 1.9 +/- 0.7 vs 2.1 +/- 1.1 h, morphine 1.3 +/- 0.7 vs 2.3 +/- 1.5 h).",Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),h,2.3,15240,DB00747,Scopolamine
,9542560,maximal effect,A heavy sedation and antisialogogue effect (VAS) was found in both groups with faster occurrence of maximal effect in group D (60 vs 120-180 min).,Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),min,60,15241,DB00747,Scopolamine
,9542560,maximal effect,A heavy sedation and antisialogogue effect (VAS) was found in both groups with faster occurrence of maximal effect in group D (60 vs 120-180 min).,Pharmacokinetics and clinical effects of intramuscular scopolamine plus morphine. A comparison of two injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542560/),min,120-180,15242,DB00747,Scopolamine
,10217331,EC50,"Mean (+/-SD) EC50, sigmoidicity factor (gamma), and equilibration rate constant (k(e0)) estimates were 1.35 (+/-0.27) ng/mL, 6.07 (+/-1.98) and 11.0 (+/-5.28) l/h for atropine and 1.35 (+/-0.49) ng/mL, 4.34 (+/-1.55) and 2.26 (+/-0.81) l/h for glycopyrrolate.",Spectral analysis of heart rate variability as a quantitative measure of parasympatholytic effect--integrated pharmacokinetics and pharmacodynamics of three anticholinergic drugs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217331/),[ng] / [ml],1.35,21557,DB00747,Scopolamine
,10217331,rate constant (k(e0)),"Mean (+/-SD) EC50, sigmoidicity factor (gamma), and equilibration rate constant (k(e0)) estimates were 1.35 (+/-0.27) ng/mL, 6.07 (+/-1.98) and 11.0 (+/-5.28) l/h for atropine and 1.35 (+/-0.49) ng/mL, 4.34 (+/-1.55) and 2.26 (+/-0.81) l/h for glycopyrrolate.",Spectral analysis of heart rate variability as a quantitative measure of parasympatholytic effect--integrated pharmacokinetics and pharmacodynamics of three anticholinergic drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217331/),[l] / [h],11.0,21558,DB00747,Scopolamine
,2762223,volume of distribution,"Mean and SE values for volume of distribution, systemic clearance, and renal clearance were 1.4 +/- 0.3 liters/kg, 65.3 +/- 5.2 liters/hr, and 4.2 +/- 1.4 liters/hr, respectively.",Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2762223/),[l] / [kg],1.4,21563,DB00747,Scopolamine
,2762223,systemic clearance,"Mean and SE values for volume of distribution, systemic clearance, and renal clearance were 1.4 +/- 0.3 liters/kg, 65.3 +/- 5.2 liters/hr, and 4.2 +/- 1.4 liters/hr, respectively.",Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2762223/),[l] / [h],65.3,21564,DB00747,Scopolamine
,2762223,renal clearance,"Mean and SE values for volume of distribution, systemic clearance, and renal clearance were 1.4 +/- 0.3 liters/kg, 65.3 +/- 5.2 liters/hr, and 4.2 +/- 1.4 liters/hr, respectively.",Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2762223/),[l] / [h],4.2,21565,DB00747,Scopolamine
,2762223,peak plasma concentrations,Mean peak plasma concentrations were 2909.8 +/- 240.9 pg/ml following iv administration and 528.6 +/- 109.4 pg/ml following oral administration.,Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2762223/),[pg] / [ml],2909.8,21566,DB00747,Scopolamine
,2762223,peak plasma concentrations,Mean peak plasma concentrations were 2909.8 +/- 240.9 pg/ml following iv administration and 528.6 +/- 109.4 pg/ml following oral administration.,Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2762223/),[pg] / [ml],528.6,21567,DB00747,Scopolamine
,2762223,Elimination half-life,Elimination half-life of the drug was 4.5 +/- 1.7 hr.,Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2762223/),h,4.5,21568,DB00747,Scopolamine
,2762223,Bioavailability,"Bioavailability of the oral dose was variable among subjects, ranging between 10.7 and 48.2%.",Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2762223/),%,10.7 and 48.2,21569,DB00747,Scopolamine
,29463072,peak plasma concentration,"A pharmacokinetic study of donepezil showed a mean peak plasma concentration of donepezil after oral treatment (3 and 10 mg/kg) of approximately 1.2 ± 0.4 h and 1.4 ± 0.5 h, respectively; absolute bioavailability was calculated as 3.6%.","The Effects of Donepezil, an Acetylcholinesterase Inhibitor, on Impaired Learning and Memory in Rodents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29463072/),h,1.2,24113,DB00747,Scopolamine
,29463072,peak plasma concentration,"A pharmacokinetic study of donepezil showed a mean peak plasma concentration of donepezil after oral treatment (3 and 10 mg/kg) of approximately 1.2 ± 0.4 h and 1.4 ± 0.5 h, respectively; absolute bioavailability was calculated as 3.6%.","The Effects of Donepezil, an Acetylcholinesterase Inhibitor, on Impaired Learning and Memory in Rodents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29463072/),h,1.4,24114,DB00747,Scopolamine
,29463072,absolute bioavailability,"A pharmacokinetic study of donepezil showed a mean peak plasma concentration of donepezil after oral treatment (3 and 10 mg/kg) of approximately 1.2 ± 0.4 h and 1.4 ± 0.5 h, respectively; absolute bioavailability was calculated as 3.6%.","The Effects of Donepezil, an Acetylcholinesterase Inhibitor, on Impaired Learning and Memory in Rodents. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29463072/),%,3.6,24115,DB00747,Scopolamine
,29463072,maximum inhibition,"Further, AChE activity was inhibited by increasing plasma concentrations of donepezil, and a maximum inhibition of 31.5 ± 5.7% was observed after donepezil treatment in hairless rats.","The Effects of Donepezil, an Acetylcholinesterase Inhibitor, on Impaired Learning and Memory in Rodents. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29463072/),%,31.5,24116,DB00747,Scopolamine
,2193993,peak plasma scopolamine concentration,The peak plasma scopolamine concentration of 550 +/- 60 pg/ml was reached within 15 minutes in all but two patients.,Systemic absorption of ocular scopolamine in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2193993/),[pg] / [ml],550,24709,DB00747,Scopolamine
,3799206,half-life,"After intravenous (N = 4) the drug fast disappeared from the circulation with a half-life of about 5 min., and the serum levels generally were measurable up to 3 hours, mean elimination half-life was 1.85 hours.",Pharmacokinetics and clinical effects of scopolamine in caesarean section patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3799206/),min,5,24949,DB00747,Scopolamine
,3799206,elimination half-life,"After intravenous (N = 4) the drug fast disappeared from the circulation with a half-life of about 5 min., and the serum levels generally were measurable up to 3 hours, mean elimination half-life was 1.85 hours.",Pharmacokinetics and clinical effects of scopolamine in caesarean section patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3799206/),h,1.85,24950,DB00747,Scopolamine
,3799206,tmax,"A fast absorption was found after intramuscular injection, tmax = 10 min.",Pharmacokinetics and clinical effects of scopolamine in caesarean section patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3799206/),min,10,24951,DB00747,Scopolamine
,3799206,tmax,"(N = 4), and the drug had a clinically significant oropharyngeal absorption as well, tmax was around 1 hour (N = 6).",Pharmacokinetics and clinical effects of scopolamine in caesarean section patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3799206/),h,1,24952,DB00747,Scopolamine
,16828890,zeta potential,"CBSA-NPs loaded with NC-1900 in spherical shape and uniform size below 100 nm were prepared by the double emulsion/solvent evaporation procedure, and the zeta potential of CBSA-NPs was about -8mV with the loading capacity of NC-1900 around 0.46%.","Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16828890/),m,-,34040,DB00747,Scopolamine
,16828890,zeta potential,"CBSA-NPs loaded with NC-1900 in spherical shape and uniform size below 100 nm were prepared by the double emulsion/solvent evaporation procedure, and the zeta potential of CBSA-NPs was about -8mV with the loading capacity of NC-1900 around 0.46%.","Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16828890/),m,8,34041,DB00747,Scopolamine
,16828890,loading capacity,"CBSA-NPs loaded with NC-1900 in spherical shape and uniform size below 100 nm were prepared by the double emulsion/solvent evaporation procedure, and the zeta potential of CBSA-NPs was about -8mV with the loading capacity of NC-1900 around 0.46%.","Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16828890/),%,0.46,34042,DB00747,Scopolamine
,16828890,half-life,"Furthermore, the half-life of NC-1900 loaded in CBSA-NPs in plasma was about 78 h, which was 4-fold longer than that of free NC-1900 (19 h).","Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16828890/),h,78,34043,DB00747,Scopolamine
,16828890,half-life,"Furthermore, the half-life of NC-1900 loaded in CBSA-NPs in plasma was about 78 h, which was 4-fold longer than that of free NC-1900 (19 h).","Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16828890/),h,19,34044,DB00747,Scopolamine
,25044356,maximum concentrations,"The maximum concentration of these three tropane alkaloids was reached within 15 min, and the maximum concentrations were 31.36 ± 7.35 ng/mL for atropine, 49.94 ± 2.67 ng/mL for scopolamine, and 2.83 ± 1.49 ng/mL for anisodamine.","Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044356/),[ng] / [ml],31.36,42316,DB00747,Scopolamine
,25044356,maximum concentrations,"The maximum concentration of these three tropane alkaloids was reached within 15 min, and the maximum concentrations were 31.36 ± 7.35 ng/mL for atropine, 49.94 ± 2.67 ng/mL for scopolamine, and 2.83 ± 1.49 ng/mL for anisodamine.","Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044356/),[ng] / [ml],49.94,42317,DB00747,Scopolamine
,25044356,maximum concentrations,"The maximum concentration of these three tropane alkaloids was reached within 15 min, and the maximum concentrations were 31.36 ± 7.35 ng/mL for atropine, 49.94 ± 2.67 ng/mL for scopolamine, and 2.83 ± 1.49 ng/mL for anisodamine.","Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044356/),[ng] / [ml],2.83,42318,DB00747,Scopolamine
,25044356,areas under the curve,"The pharmacokinetic parameters revealed areas under the curve of 22.76 ± 5.80, 16.80 ± 3.08, and 4.31 ± 1.21 ng/h mL and mean residence times of 2.08 ± 0.55, 1.19 ± 0.45, and 3.28 ± 0.78 h for atropine, scopolamine, and anisodamine, respectively.","Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044356/),[ng] / [h·ml],22.76,42319,DB00747,Scopolamine
,25044356,areas under the curve,"The pharmacokinetic parameters revealed areas under the curve of 22.76 ± 5.80, 16.80 ± 3.08, and 4.31 ± 1.21 ng/h mL and mean residence times of 2.08 ± 0.55, 1.19 ± 0.45, and 3.28 ± 0.78 h for atropine, scopolamine, and anisodamine, respectively.","Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044356/),[ng] / [h·ml],16.80,42320,DB00747,Scopolamine
,25044356,areas under the curve,"The pharmacokinetic parameters revealed areas under the curve of 22.76 ± 5.80, 16.80 ± 3.08, and 4.31 ± 1.21 ng/h mL and mean residence times of 2.08 ± 0.55, 1.19 ± 0.45, and 3.28 ± 0.78 h for atropine, scopolamine, and anisodamine, respectively.","Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044356/),[ng] / [h·ml],4.31,42321,DB00747,Scopolamine
,25044356,mean residence times,"The pharmacokinetic parameters revealed areas under the curve of 22.76 ± 5.80, 16.80 ± 3.08, and 4.31 ± 1.21 ng/h mL and mean residence times of 2.08 ± 0.55, 1.19 ± 0.45, and 3.28 ± 0.78 h for atropine, scopolamine, and anisodamine, respectively.","Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044356/),h,2.08,42322,DB00747,Scopolamine
,25044356,mean residence times,"The pharmacokinetic parameters revealed areas under the curve of 22.76 ± 5.80, 16.80 ± 3.08, and 4.31 ± 1.21 ng/h mL and mean residence times of 2.08 ± 0.55, 1.19 ± 0.45, and 3.28 ± 0.78 h for atropine, scopolamine, and anisodamine, respectively.","Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044356/),h,1.19,42323,DB00747,Scopolamine
,25044356,mean residence times,"The pharmacokinetic parameters revealed areas under the curve of 22.76 ± 5.80, 16.80 ± 3.08, and 4.31 ± 1.21 ng/h mL and mean residence times of 2.08 ± 0.55, 1.19 ± 0.45, and 3.28 ± 0.78 h for atropine, scopolamine, and anisodamine, respectively.","Simultaneous determination of atropine, scopolamine, and anisodamine from Hyoscyamus niger L. in rat plasma by high-performance liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetics study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044356/),h,3.28,42324,DB00747,Scopolamine
,31561043,IC50,"In particular, compound 49 containing 2,4-difluoro substitution at terminal phenyl ring considered as most potential lead with inhibition of acetylcholinesterase (hAChE, IC50 = 0.054 μM), butyrylcholinesterase (hBChE, IC50 = 0.787 μM) and beta-secretase-1 (hBACE-1, IC50 = 0.098 μM).","Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31561043/),μM,0.054,47290,DB00747,Scopolamine
,31561043,IC50,"In particular, compound 49 containing 2,4-difluoro substitution at terminal phenyl ring considered as most potential lead with inhibition of acetylcholinesterase (hAChE, IC50 = 0.054 μM), butyrylcholinesterase (hBChE, IC50 = 0.787 μM) and beta-secretase-1 (hBACE-1, IC50 = 0.098 μM).","Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31561043/),μM,0.787,47291,DB00747,Scopolamine
,31561043,IC50,"In particular, compound 49 containing 2,4-difluoro substitution at terminal phenyl ring considered as most potential lead with inhibition of acetylcholinesterase (hAChE, IC50 = 0.054 μM), butyrylcholinesterase (hBChE, IC50 = 0.787 μM) and beta-secretase-1 (hBACE-1, IC50 = 0.098 μM).","Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31561043/),μM,0.098,47292,DB00747,Scopolamine
,31561043,Ki,The enzyme kinetics study of 49 against hAChE suggested a mixed type of inhibition (Ki = 0.030 μM).,"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31561043/),μM,0.030,47293,DB00747,Scopolamine
,2077523,limit of detection,"The limit of detection of the assay was 70 ng/l in plasma, 2 micrograms/l in urine and 140 ng/l in CSF.",Radioreceptor assay for pharmacokinetic studies of glycopyrrolate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2077523/),[ng] / [l],70,54218,DB00747,Scopolamine
,2077523,limit of detection,"The limit of detection of the assay was 70 ng/l in plasma, 2 micrograms/l in urine and 140 ng/l in CSF.",Radioreceptor assay for pharmacokinetic studies of glycopyrrolate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2077523/),[μg] / [l],2,54219,DB00747,Scopolamine
,2077523,limit of detection,"The limit of detection of the assay was 70 ng/l in plasma, 2 micrograms/l in urine and 140 ng/l in CSF.",Radioreceptor assay for pharmacokinetic studies of glycopyrrolate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2077523/),[ng] / [l],140,54220,DB00747,Scopolamine
,2077523,maximum plasma concentration (Cmax),A very rapid absorption was found with a mean maximum plasma concentration (Cmax) of 14.26 (range 12.02-16.97) micrograms/l and mean Tmax (time to Cmax) of 13.3 (range 10-15) min. and almost 50% of the dose administered was excreted into the urine within 3 hr.,Radioreceptor assay for pharmacokinetic studies of glycopyrrolate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2077523/),[μg] / [l],14.26,54221,DB00747,Scopolamine
,2077523,Tmax (time to Cmax),A very rapid absorption was found with a mean maximum plasma concentration (Cmax) of 14.26 (range 12.02-16.97) micrograms/l and mean Tmax (time to Cmax) of 13.3 (range 10-15) min. and almost 50% of the dose administered was excreted into the urine within 3 hr.,Radioreceptor assay for pharmacokinetic studies of glycopyrrolate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2077523/),min,13.3,54222,DB00747,Scopolamine
,22007521,C(max),The pharmacokinetic parameters of test tablet vs reference tablet were as follows: C(max): (8.16 +/- 0.67) ng x mL(-1) vs (3.54 +/- 0.64) ng x mL(-1); t1/2: (2.83 +/- 0.45) h vs (3.85 +/- 0.82) h; t(max): (1.25 +/- 0.27) h vs (0.42 +/- 0.09) h; AUC(0-12h): (25.06 +/- 3.75) h x ng x mL(-1) vs (9.59 +/- 1.02) h x ng x mL(-1); AUC(0-infinity): (26.30 +/- 3.92) h x ng x mL(-1) vs (10.80 +/- 1.45) h x ng x mL(-1); MRT(0-12h): (3.38 +/- 0.34) h vs (3.86 +/- 0.26) h; MRT(0-infinity): (3.98 +/- 0.63) h vs (5.37 +/- 1.00) h.,[Pharmacokinetics of scopolamine hydrobromide oral disintegrative microencapsule tablets in Beagle dogs determined with LC-MS/MS]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007521/),[ng] / [ml],8.16,54919,DB00747,Scopolamine
,22007521,C(max),The pharmacokinetic parameters of test tablet vs reference tablet were as follows: C(max): (8.16 +/- 0.67) ng x mL(-1) vs (3.54 +/- 0.64) ng x mL(-1); t1/2: (2.83 +/- 0.45) h vs (3.85 +/- 0.82) h; t(max): (1.25 +/- 0.27) h vs (0.42 +/- 0.09) h; AUC(0-12h): (25.06 +/- 3.75) h x ng x mL(-1) vs (9.59 +/- 1.02) h x ng x mL(-1); AUC(0-infinity): (26.30 +/- 3.92) h x ng x mL(-1) vs (10.80 +/- 1.45) h x ng x mL(-1); MRT(0-12h): (3.38 +/- 0.34) h vs (3.86 +/- 0.26) h; MRT(0-infinity): (3.98 +/- 0.63) h vs (5.37 +/- 1.00) h.,[Pharmacokinetics of scopolamine hydrobromide oral disintegrative microencapsule tablets in Beagle dogs determined with LC-MS/MS]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007521/),[ng] / [ml],3.54,54920,DB00747,Scopolamine
,22007521,t1/2,The pharmacokinetic parameters of test tablet vs reference tablet were as follows: C(max): (8.16 +/- 0.67) ng x mL(-1) vs (3.54 +/- 0.64) ng x mL(-1); t1/2: (2.83 +/- 0.45) h vs (3.85 +/- 0.82) h; t(max): (1.25 +/- 0.27) h vs (0.42 +/- 0.09) h; AUC(0-12h): (25.06 +/- 3.75) h x ng x mL(-1) vs (9.59 +/- 1.02) h x ng x mL(-1); AUC(0-infinity): (26.30 +/- 3.92) h x ng x mL(-1) vs (10.80 +/- 1.45) h x ng x mL(-1); MRT(0-12h): (3.38 +/- 0.34) h vs (3.86 +/- 0.26) h; MRT(0-infinity): (3.98 +/- 0.63) h vs (5.37 +/- 1.00) h.,[Pharmacokinetics of scopolamine hydrobromide oral disintegrative microencapsule tablets in Beagle dogs determined with LC-MS/MS]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007521/),h,2.83,54921,DB00747,Scopolamine
,22007521,t1/2,The pharmacokinetic parameters of test tablet vs reference tablet were as follows: C(max): (8.16 +/- 0.67) ng x mL(-1) vs (3.54 +/- 0.64) ng x mL(-1); t1/2: (2.83 +/- 0.45) h vs (3.85 +/- 0.82) h; t(max): (1.25 +/- 0.27) h vs (0.42 +/- 0.09) h; AUC(0-12h): (25.06 +/- 3.75) h x ng x mL(-1) vs (9.59 +/- 1.02) h x ng x mL(-1); AUC(0-infinity): (26.30 +/- 3.92) h x ng x mL(-1) vs (10.80 +/- 1.45) h x ng x mL(-1); MRT(0-12h): (3.38 +/- 0.34) h vs (3.86 +/- 0.26) h; MRT(0-infinity): (3.98 +/- 0.63) h vs (5.37 +/- 1.00) h.,[Pharmacokinetics of scopolamine hydrobromide oral disintegrative microencapsule tablets in Beagle dogs determined with LC-MS/MS]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007521/),h,3.85,54922,DB00747,Scopolamine
,22007521,t(max),The pharmacokinetic parameters of test tablet vs reference tablet were as follows: C(max): (8.16 +/- 0.67) ng x mL(-1) vs (3.54 +/- 0.64) ng x mL(-1); t1/2: (2.83 +/- 0.45) h vs (3.85 +/- 0.82) h; t(max): (1.25 +/- 0.27) h vs (0.42 +/- 0.09) h; AUC(0-12h): (25.06 +/- 3.75) h x ng x mL(-1) vs (9.59 +/- 1.02) h x ng x mL(-1); AUC(0-infinity): (26.30 +/- 3.92) h x ng x mL(-1) vs (10.80 +/- 1.45) h x ng x mL(-1); MRT(0-12h): (3.38 +/- 0.34) h vs (3.86 +/- 0.26) h; MRT(0-infinity): (3.98 +/- 0.63) h vs (5.37 +/- 1.00) h.,[Pharmacokinetics of scopolamine hydrobromide oral disintegrative microencapsule tablets in Beagle dogs determined with LC-MS/MS]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007521/),h,1.25,54923,DB00747,Scopolamine
,22007521,t(max),The pharmacokinetic parameters of test tablet vs reference tablet were as follows: C(max): (8.16 +/- 0.67) ng x mL(-1) vs (3.54 +/- 0.64) ng x mL(-1); t1/2: (2.83 +/- 0.45) h vs (3.85 +/- 0.82) h; t(max): (1.25 +/- 0.27) h vs (0.42 +/- 0.09) h; AUC(0-12h): (25.06 +/- 3.75) h x ng x mL(-1) vs (9.59 +/- 1.02) h x ng x mL(-1); AUC(0-infinity): (26.30 +/- 3.92) h x ng x mL(-1) vs (10.80 +/- 1.45) h x ng x mL(-1); MRT(0-12h): (3.38 +/- 0.34) h vs (3.86 +/- 0.26) h; MRT(0-infinity): (3.98 +/- 0.63) h vs (5.37 +/- 1.00) h.,[Pharmacokinetics of scopolamine hydrobromide oral disintegrative microencapsule tablets in Beagle dogs determined with LC-MS/MS]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007521/),h,0.42,54924,DB00747,Scopolamine
,22007521,AUC(0-12h),The pharmacokinetic parameters of test tablet vs reference tablet were as follows: C(max): (8.16 +/- 0.67) ng x mL(-1) vs (3.54 +/- 0.64) ng x mL(-1); t1/2: (2.83 +/- 0.45) h vs (3.85 +/- 0.82) h; t(max): (1.25 +/- 0.27) h vs (0.42 +/- 0.09) h; AUC(0-12h): (25.06 +/- 3.75) h x ng x mL(-1) vs (9.59 +/- 1.02) h x ng x mL(-1); AUC(0-infinity): (26.30 +/- 3.92) h x ng x mL(-1) vs (10.80 +/- 1.45) h x ng x mL(-1); MRT(0-12h): (3.38 +/- 0.34) h vs (3.86 +/- 0.26) h; MRT(0-infinity): (3.98 +/- 0.63) h vs (5.37 +/- 1.00) h.,[Pharmacokinetics of scopolamine hydrobromide oral disintegrative microencapsule tablets in Beagle dogs determined with LC-MS/MS]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007521/),[h·ng] / [ml],25.06,54925,DB00747,Scopolamine
,22007521,AUC(0-12h),The pharmacokinetic parameters of test tablet vs reference tablet were as follows: C(max): (8.16 +/- 0.67) ng x mL(-1) vs (3.54 +/- 0.64) ng x mL(-1); t1/2: (2.83 +/- 0.45) h vs (3.85 +/- 0.82) h; t(max): (1.25 +/- 0.27) h vs (0.42 +/- 0.09) h; AUC(0-12h): (25.06 +/- 3.75) h x ng x mL(-1) vs (9.59 +/- 1.02) h x ng x mL(-1); AUC(0-infinity): (26.30 +/- 3.92) h x ng x mL(-1) vs (10.80 +/- 1.45) h x ng x mL(-1); MRT(0-12h): (3.38 +/- 0.34) h vs (3.86 +/- 0.26) h; MRT(0-infinity): (3.98 +/- 0.63) h vs (5.37 +/- 1.00) h.,[Pharmacokinetics of scopolamine hydrobromide oral disintegrative microencapsule tablets in Beagle dogs determined with LC-MS/MS]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007521/),[h·ng] / [ml],9.59,54926,DB00747,Scopolamine
,22007521,AUC(0-infinity),The pharmacokinetic parameters of test tablet vs reference tablet were as follows: C(max): (8.16 +/- 0.67) ng x mL(-1) vs (3.54 +/- 0.64) ng x mL(-1); t1/2: (2.83 +/- 0.45) h vs (3.85 +/- 0.82) h; t(max): (1.25 +/- 0.27) h vs (0.42 +/- 0.09) h; AUC(0-12h): (25.06 +/- 3.75) h x ng x mL(-1) vs (9.59 +/- 1.02) h x ng x mL(-1); AUC(0-infinity): (26.30 +/- 3.92) h x ng x mL(-1) vs (10.80 +/- 1.45) h x ng x mL(-1); MRT(0-12h): (3.38 +/- 0.34) h vs (3.86 +/- 0.26) h; MRT(0-infinity): (3.98 +/- 0.63) h vs (5.37 +/- 1.00) h.,[Pharmacokinetics of scopolamine hydrobromide oral disintegrative microencapsule tablets in Beagle dogs determined with LC-MS/MS]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007521/),[h·ng] / [ml],26.30,54927,DB00747,Scopolamine
,22007521,AUC(0-infinity),The pharmacokinetic parameters of test tablet vs reference tablet were as follows: C(max): (8.16 +/- 0.67) ng x mL(-1) vs (3.54 +/- 0.64) ng x mL(-1); t1/2: (2.83 +/- 0.45) h vs (3.85 +/- 0.82) h; t(max): (1.25 +/- 0.27) h vs (0.42 +/- 0.09) h; AUC(0-12h): (25.06 +/- 3.75) h x ng x mL(-1) vs (9.59 +/- 1.02) h x ng x mL(-1); AUC(0-infinity): (26.30 +/- 3.92) h x ng x mL(-1) vs (10.80 +/- 1.45) h x ng x mL(-1); MRT(0-12h): (3.38 +/- 0.34) h vs (3.86 +/- 0.26) h; MRT(0-infinity): (3.98 +/- 0.63) h vs (5.37 +/- 1.00) h.,[Pharmacokinetics of scopolamine hydrobromide oral disintegrative microencapsule tablets in Beagle dogs determined with LC-MS/MS]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007521/),[h·ng] / [ml],10.80,54928,DB00747,Scopolamine
,22007521,MRT(0-12h),The pharmacokinetic parameters of test tablet vs reference tablet were as follows: C(max): (8.16 +/- 0.67) ng x mL(-1) vs (3.54 +/- 0.64) ng x mL(-1); t1/2: (2.83 +/- 0.45) h vs (3.85 +/- 0.82) h; t(max): (1.25 +/- 0.27) h vs (0.42 +/- 0.09) h; AUC(0-12h): (25.06 +/- 3.75) h x ng x mL(-1) vs (9.59 +/- 1.02) h x ng x mL(-1); AUC(0-infinity): (26.30 +/- 3.92) h x ng x mL(-1) vs (10.80 +/- 1.45) h x ng x mL(-1); MRT(0-12h): (3.38 +/- 0.34) h vs (3.86 +/- 0.26) h; MRT(0-infinity): (3.98 +/- 0.63) h vs (5.37 +/- 1.00) h.,[Pharmacokinetics of scopolamine hydrobromide oral disintegrative microencapsule tablets in Beagle dogs determined with LC-MS/MS]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007521/),h,3.38,54929,DB00747,Scopolamine
,17520450,Cmax,"Following delivery of the sublingual spray dose, the average Cmax was 1024.4+/-177 ng/mL, and the AUC value was found to be 61067.6+/-9605 ng.min/mL.",Scopolamine sublingual spray: an alternative route of delivery for the treatment of motion sickness. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520450/),[ng] / [ml],1024.4,58694,DB00747,Scopolamine
,17520450,AUC,"Following delivery of the sublingual spray dose, the average Cmax was 1024.4+/-177 ng/mL, and the AUC value was found to be 61067.6+/-9605 ng.min/mL.",Scopolamine sublingual spray: an alternative route of delivery for the treatment of motion sickness. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520450/),[min·ng] / [ml],61067.6,58695,DB00747,Scopolamine
,17520450,bioavailability,"Relative to the intravenous dose (100% bioavailability), the bioavailability was 79.8% after sublingual spray administration.",Scopolamine sublingual spray: an alternative route of delivery for the treatment of motion sickness. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520450/),%,79.8,58696,DB00747,Scopolamine
,21306419,t(1/2) k(eo),"t(1/2) k(eo) for heart rate was 17 min, saccadic eye movements and adaptive tracking 1-1.5 h, body sway, smooth pursuit, visual analogue scales alertness and psychedelic 2.5-3.5 h, pupil size, finger tapping and visual analogue scales feeling high more than 8 h.",Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21306419/),min,17,60221,DB00747,Scopolamine
,21306419,t(1/2) k(eo),"t(1/2) k(eo) for heart rate was 17 min, saccadic eye movements and adaptive tracking 1-1.5 h, body sway, smooth pursuit, visual analogue scales alertness and psychedelic 2.5-3.5 h, pupil size, finger tapping and visual analogue scales feeling high more than 8 h.",Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21306419/),h,1-1.5,60222,DB00747,Scopolamine
,21306419,t(1/2) k(eo),"t(1/2) k(eo) for heart rate was 17 min, saccadic eye movements and adaptive tracking 1-1.5 h, body sway, smooth pursuit, visual analogue scales alertness and psychedelic 2.5-3.5 h, pupil size, finger tapping and visual analogue scales feeling high more than 8 h.",Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21306419/),h,2.5-3.5,60223,DB00747,Scopolamine
,31887472,IC50,Compound 6j was the most potent inhibitor of AChE (IC50 = 0.068 µM).,"Design, synthesis, and biological evaluation of ferulic acid based 1,3,4-oxadiazole hybrids as multifunctional therapeutics for the treatment of Alzheimer's disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887472/),μM,0.068,63688,DB00747,Scopolamine
,31887472,IC50,"It also showed equipotent inhibition of BChE and BACE-1 with IC50 values of 0.218 µM and 0.255 µM, respectively.","Design, synthesis, and biological evaluation of ferulic acid based 1,3,4-oxadiazole hybrids as multifunctional therapeutics for the treatment of Alzheimer's disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887472/),μM,0.218,63689,DB00747,Scopolamine
,31887472,IC50,"It also showed equipotent inhibition of BChE and BACE-1 with IC50 values of 0.218 µM and 0.255 µM, respectively.","Design, synthesis, and biological evaluation of ferulic acid based 1,3,4-oxadiazole hybrids as multifunctional therapeutics for the treatment of Alzheimer's disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887472/),μM,0.255,63690,DB00747,Scopolamine
,31887472,IC50,"Compound 6k possessed the most significant inhibition of BChE and BACE-1 with IC50 values, 0.163 µM and 0.211 µM, respectively.","Design, synthesis, and biological evaluation of ferulic acid based 1,3,4-oxadiazole hybrids as multifunctional therapeutics for the treatment of Alzheimer's disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887472/),μM,0.163,63691,DB00747,Scopolamine
,31887472,IC50,"Compound 6k possessed the most significant inhibition of BChE and BACE-1 with IC50 values, 0.163 µM and 0.211 µM, respectively.","Design, synthesis, and biological evaluation of ferulic acid based 1,3,4-oxadiazole hybrids as multifunctional therapeutics for the treatment of Alzheimer's disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887472/),μM,0.211,63692,DB00747,Scopolamine
,9725548,peak serum concentrations,"Mean peak serum concentrations (free base) were 3.27, 8.99, and 18.81 ng/mL after administration of 0.4, 0.6 mg, and 0.8 mg scopolamine, respectively.",Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725548/),[ng] / [ml],3.27,68951,DB00747,Scopolamine
,9725548,peak serum concentrations,"Mean peak serum concentrations (free base) were 3.27, 8.99, and 18.81 ng/mL after administration of 0.4, 0.6 mg, and 0.8 mg scopolamine, respectively.",Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725548/),[ng] / [ml],8.99,68952,DB00747,Scopolamine
,9725548,peak serum concentrations,"Mean peak serum concentrations (free base) were 3.27, 8.99, and 18.81 ng/mL after administration of 0.4, 0.6 mg, and 0.8 mg scopolamine, respectively.",Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725548/),[ng] / [ml],18.81,68953,DB00747,Scopolamine
,9725548,Elimination half-life,Elimination half-life was approximately 220 minutes.,Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725548/),min,220,68954,DB00747,Scopolamine
,11745922,Cl,Both drugs are highly cleared (Cl between 87 and 150 ml min(-1) kg(-1)) and extensively distributed into tissues (volume of distribution V(ss) between 3 and 15 l kg(-1)).,Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745922/),[ml] / [kg·min],87 and 150,90935,DB00747,Scopolamine
,11745922,volume of distribution V(ss),Both drugs are highly cleared (Cl between 87 and 150 ml min(-1) kg(-1)) and extensively distributed into tissues (volume of distribution V(ss) between 3 and 15 l kg(-1)).,Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745922/),[l] / [kg],3 and 15,90936,DB00747,Scopolamine
,11745922,Cl,"In dogs, this holds also true for both drugs (Cl between 34 and 42 ml min(-1) kg(-1), V(ss) between 2 and 10 l kg(-1)), although different dose regimen were applied (i.v. bolus of 0.08 mg kg(-1) vs. infusion of 0.1 mg kg(-1) h(-1) for 3 h).",Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745922/),[ml] / [kg·min],34 and 42,90937,DB00747,Scopolamine
,11745922,V(ss),"In dogs, this holds also true for both drugs (Cl between 34 and 42 ml min(-1) kg(-1), V(ss) between 2 and 10 l kg(-1)), although different dose regimen were applied (i.v. bolus of 0.08 mg kg(-1) vs. infusion of 0.1 mg kg(-1) h(-1) for 3 h).",Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745922/),[l] / [kg],2 and 10,90938,DB00747,Scopolamine
,11745922,terminal elimination half-life,"Both ipratropium and tiotropium showed a comparable terminal elimination half-life in rat urine (21-24 h) after single i.v. administration, which was much longer than the corresponding half-life in plasma (6-8 h).",Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745922/),h,21-24,90939,DB00747,Scopolamine
,11745922,half-life,"Both ipratropium and tiotropium showed a comparable terminal elimination half-life in rat urine (21-24 h) after single i.v. administration, which was much longer than the corresponding half-life in plasma (6-8 h).",Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745922/),h,6-8,90940,DB00747,Scopolamine
,11920924,inhibition,Whole-blood cholinesterase inhibition was 15-20%.,Prophylaxis against organophosphate poisoning by sustained release of scopolamine and physostigmine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920924/),%,15-20,99111,DB00747,Scopolamine
,22035851,peak IC,"On average, peak IC and AUC(0-4) for IC were significantly greater after indacaterol than placebo by 177 mL (p = 0.007) and 142 mL (p = 0.001), respectively.",Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22035851/),ml,177,99417,DB00747,Scopolamine
,22035851,AUC(0-4),"On average, peak IC and AUC(0-4) for IC were significantly greater after indacaterol than placebo by 177 mL (p = 0.007) and 142 mL (p = 0.001), respectively.",Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22035851/),ml,142,99418,DB00747,Scopolamine
,22035851,peak IC,"Differences in peak IC and AUC(0-4) for IC between tiotropium and placebo were 120 mL (p = 0.07) and 85 mL (p = 0.052), respectively.",Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22035851/),ml,120,99419,DB00747,Scopolamine
,22035851,AUC(0-4),"Differences in peak IC and AUC(0-4) for IC between tiotropium and placebo were 120 mL (p = 0.07) and 85 mL (p = 0.052), respectively.",Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22035851/),ml,85,99420,DB00747,Scopolamine
,19290944,protective times,"Group median protective times for the first regimen were 54.45 h for SCO and 64.35 h for PHY, and for the second regimen 63.75 h for SCO and 0 h for PHY.",Evaluation of two scopolamine and physostigmine pretreatment regimens against nerve agent poisoning in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19290944/),h,54.45,105109,DB00747,Scopolamine
,19290944,protective times,"Group median protective times for the first regimen were 54.45 h for SCO and 64.35 h for PHY, and for the second regimen 63.75 h for SCO and 0 h for PHY.",Evaluation of two scopolamine and physostigmine pretreatment regimens against nerve agent poisoning in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19290944/),h,64.35,105110,DB00747,Scopolamine
,19290944,protective times,"Group median protective times for the first regimen were 54.45 h for SCO and 64.35 h for PHY, and for the second regimen 63.75 h for SCO and 0 h for PHY.",Evaluation of two scopolamine and physostigmine pretreatment regimens against nerve agent poisoning in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19290944/),h,63.75,105111,DB00747,Scopolamine
,19290944,protective times,"Group median protective times for the first regimen were 54.45 h for SCO and 64.35 h for PHY, and for the second regimen 63.75 h for SCO and 0 h for PHY.",Evaluation of two scopolamine and physostigmine pretreatment regimens against nerve agent poisoning in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19290944/),h,0,105112,DB00747,Scopolamine
,27273555,apparent central,"The estimated scopolamine population mean apparent central and peripheral volume of distribution was 2.66 ± 1.050 l and 62.10 ± 10.100 l, respectively and the clearance was 1.09 ± 0.096 l min(-1) .",Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27273555/),l,2.66,108042,DB00747,Scopolamine
,27273555,peripheral volume of distribution,"The estimated scopolamine population mean apparent central and peripheral volume of distribution was 2.66 ± 1.050 l and 62.10 ± 10.100 l, respectively and the clearance was 1.09 ± 0.096 l min(-1) .",Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27273555/),l,62.10,108043,DB00747,Scopolamine
,27273555,clearance,"The estimated scopolamine population mean apparent central and peripheral volume of distribution was 2.66 ± 1.050 l and 62.10 ± 10.100 l, respectively and the clearance was 1.09 ± 0.096 l min(-1) .",Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27273555/),[l] / [min],1.09,108044,DB00747,Scopolamine
,24165906,"tmax,ss","Tiotropium was rapidly absorbed with a median tmax,ss of 5-7 minutes postdosing for both devices.",Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24165906/),min,5-7,109146,DB00747,Scopolamine
,18492357,plasma extraction recovery,The mean plasma extraction recovery of tiotropium is 92.3 +/- 5.0%.,Sensitive HPLC-ESI-MS method for the determination of tiotropium in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18492357/),%,92.3,109395,DB00747,Scopolamine
,10579809,specific activity,"The active (R)-isomer (pKb = 10.92) was labeled by reacting [(11)C]-CH(3)I with the secondary amine precursor (40-60% decay-corrected radiochemical yield, specific activity 13.0-34.3 TBq/mmol, 45 min after end of bombardment).","Preclinical testing of N-[(11)c]-methyl-piperidin-4-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate, a novel radioligand for detection of cerebral muscarinic receptors using PET. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579809/),[tbq] / [mM],13.0-34.3,110628,DB00747,Scopolamine
,10579809,standard uptake values (SUVs),"Brain uptake of (R)-[(11)C]-VC-004 was high, standard uptake values (SUVs) ranging from 1.6 in cerebellum to 3.3 in frontal cortex.","Preclinical testing of N-[(11)c]-methyl-piperidin-4-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate, a novel radioligand for detection of cerebral muscarinic receptors using PET. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579809/),,1.6,110629,DB00747,Scopolamine
,10579809,standard uptake values (SUVs),"Brain uptake of (R)-[(11)C]-VC-004 was high, standard uptake values (SUVs) ranging from 1.6 in cerebellum to 3.3 in frontal cortex.","Preclinical testing of N-[(11)c]-methyl-piperidin-4-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate, a novel radioligand for detection of cerebral muscarinic receptors using PET. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579809/),,3.3,110630,DB00747,Scopolamine
,10579809,half-life,(R)-[(11)C]VC-004 was rapidly cleared from plasma (92% with a half-life of 0.27 min) and the fraction of total plasma radioactivity representing parent compound decreased from 99% to 42% at 10 min postinjection.,"Preclinical testing of N-[(11)c]-methyl-piperidin-4-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate, a novel radioligand for detection of cerebral muscarinic receptors using PET. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579809/),min,0.27,110631,DB00747,Scopolamine
,20483954,maximal plasma unbound propiverine equivalents (C(max)),"The sum of maximal plasma unbound propiverine equivalents (C(max)) after the oral administration of propiverine at doses of 24.8, 74.3, and 248 micromol/kg was 66.0, 303, and 509 nM, respectively.",The N-oxide metabolite contributes to bladder selectivity resulting from oral propiverine: muscarinic receptor binding and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20483954/),nM,66.0,110676,DB00747,Scopolamine
,20483954,maximal plasma unbound propiverine equivalents (C(max)),"The sum of maximal plasma unbound propiverine equivalents (C(max)) after the oral administration of propiverine at doses of 24.8, 74.3, and 248 micromol/kg was 66.0, 303, and 509 nM, respectively.",The N-oxide metabolite contributes to bladder selectivity resulting from oral propiverine: muscarinic receptor binding and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20483954/),nM,303,110677,DB00747,Scopolamine
,20483954,maximal plasma unbound propiverine equivalents (C(max)),"The sum of maximal plasma unbound propiverine equivalents (C(max)) after the oral administration of propiverine at doses of 24.8, 74.3, and 248 micromol/kg was 66.0, 303, and 509 nM, respectively.",The N-oxide metabolite contributes to bladder selectivity resulting from oral propiverine: muscarinic receptor binding and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20483954/),nM,509,110678,DB00747,Scopolamine
,20483954,area under the time-concentration curve from 0 to 12 h,"The sum of corresponding area under the time-concentration curve from 0 to 12 h was 194, 2123, and 4645 nM . h, respectively.",The N-oxide metabolite contributes to bladder selectivity resulting from oral propiverine: muscarinic receptor binding and pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20483954/),h·nM,194,110679,DB00747,Scopolamine
,20483954,area under the time-concentration curve from 0 to 12 h,"The sum of corresponding area under the time-concentration curve from 0 to 12 h was 194, 2123, and 4645 nM . h, respectively.",The N-oxide metabolite contributes to bladder selectivity resulting from oral propiverine: muscarinic receptor binding and pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20483954/),h·nM,2123,110680,DB00747,Scopolamine
,20483954,area under the time-concentration curve from 0 to 12 h,"The sum of corresponding area under the time-concentration curve from 0 to 12 h was 194, 2123, and 4645 nM . h, respectively.",The N-oxide metabolite contributes to bladder selectivity resulting from oral propiverine: muscarinic receptor binding and pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20483954/),h·nM,4645,110681,DB00747,Scopolamine
,2962877,peak plasma concentration,The peak plasma concentration in three healthy volunteers (means = 322 pg/ml) occurred within 1-3 h.,Radioreceptor assay for determination of the antimuscarinic drug ipratropium bromide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2962877/),[pg] / [ml],322,113674,DB00747,Scopolamine
,19537837,AUC(0-3),"At 6 weeks, FEV(1) AUC(0-3) was significantly greater in the formoterol group compared with the placebo group (1.57 vs 1.38 L [p < 0.0001]).","Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537837/),l,1.57,114020,DB00747,Scopolamine
,19537837,AUC(0-3),"At 6 weeks, FEV(1) AUC(0-3) was significantly greater in the formoterol group compared with the placebo group (1.57 vs 1.38 L [p < 0.0001]).","Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537837/),l,1.38,114021,DB00747,Scopolamine
,19652502,pD(2),"The pD(2) value in the absence and presence of HE (10 mg/ml) was 5.14+/-0.16 and 3.99+/-0.17, respectively.",Pharmacological effects of Hachi-mi-jio-gan extract (Harncare) on the contractile response and on pharmacologically relevant receptors in the rat bladder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19652502/),,5.14,117809,DB00747,Scopolamine
,19652502,pD(2),"The pD(2) value in the absence and presence of HE (10 mg/ml) was 5.14+/-0.16 and 3.99+/-0.17, respectively.",Pharmacological effects of Hachi-mi-jio-gan extract (Harncare) on the contractile response and on pharmacologically relevant receptors in the rat bladder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19652502/),,3.99,117810,DB00747,Scopolamine
,19652502,IC(50),"The respective IC(50) values were 6.85+/-0.94, 7.08+/-0.72 and 1.34+/-0.23 mg/ml.",Pharmacological effects of Hachi-mi-jio-gan extract (Harncare) on the contractile response and on pharmacologically relevant receptors in the rat bladder. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19652502/),[mg] / [ml],6.85,117811,DB00747,Scopolamine
,19652502,IC(50),"The respective IC(50) values were 6.85+/-0.94, 7.08+/-0.72 and 1.34+/-0.23 mg/ml.",Pharmacological effects of Hachi-mi-jio-gan extract (Harncare) on the contractile response and on pharmacologically relevant receptors in the rat bladder. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19652502/),[mg] / [ml],7.08,117812,DB00747,Scopolamine
,19652502,IC(50),"The respective IC(50) values were 6.85+/-0.94, 7.08+/-0.72 and 1.34+/-0.23 mg/ml.",Pharmacological effects of Hachi-mi-jio-gan extract (Harncare) on the contractile response and on pharmacologically relevant receptors in the rat bladder. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19652502/),[mg] / [ml],1.34,117813,DB00747,Scopolamine
,2295106,elimination,"After surgery the times to awakening and extubation, and alfentanil elimination half-life (t1/2B = 0.693/-k) were determined for each patient.",Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),,0.693,122218,DB00747,Scopolamine
,2295106,times to awakening,The times to awakening and extubation for all patients were 3.2 +/- 0.6 and 8.8 +/- 1.2 hr (mean +/- SEM) respectively.,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,3.2,122219,DB00747,Scopolamine
,2295106,extubation,The times to awakening and extubation for all patients were 3.2 +/- 0.6 and 8.8 +/- 1.2 hr (mean +/- SEM) respectively.,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,8.8,122220,DB00747,Scopolamine
,2295106,elimination half-life,The elimination half-life for all patients was 5.1 +/- 1.0 hr (mean +/- SEM).,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,5.1,122221,DB00747,Scopolamine
,19042837,time to administration,There was no difference in the median time to administration of the second medication (3 hours).,"A pilot phase II randomized, cross-over, double-blinded, controlled efficacy study of octreotide versus hyoscine hydrobromide for control of noisy breathing at the end-of-life. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19042837/),h,3,123177,DB00747,Scopolamine
,29195794,IC50,"Compounds 54, 56, 59 and 64 displayed appreciable activity with an IC50 value of 14.06 µM, 12.30 µM, 14.06 µM and 12.01 µM, respectively towards acetylcholinesterase inhibition.","Design, synthesis and pharmacological evaluation of some novel indanone derivatives as acetylcholinesterase inhibitors for the management of cognitive dysfunction. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29195794/),μM,14.06,123367,DB00747,Scopolamine
,29195794,IC50,"Compounds 54, 56, 59 and 64 displayed appreciable activity with an IC50 value of 14.06 µM, 12.30 µM, 14.06 µM and 12.01 µM, respectively towards acetylcholinesterase inhibition.","Design, synthesis and pharmacological evaluation of some novel indanone derivatives as acetylcholinesterase inhibitors for the management of cognitive dysfunction. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29195794/),μM,12.30,123368,DB00747,Scopolamine
,29195794,IC50,"Compounds 54, 56, 59 and 64 displayed appreciable activity with an IC50 value of 14.06 µM, 12.30 µM, 14.06 µM and 12.01 µM, respectively towards acetylcholinesterase inhibition.","Design, synthesis and pharmacological evaluation of some novel indanone derivatives as acetylcholinesterase inhibitors for the management of cognitive dysfunction. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29195794/),μM,12.01,123369,DB00747,Scopolamine
,18525282,Tmax,Lower Tmax values (60 min) after intranasal compared with intravenous administration (120 min) suggested selective nose-to-brain transport.,Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18525282/),min,60,127524,DB00747,Scopolamine
,18525282,Tmax,Lower Tmax values (60 min) after intranasal compared with intravenous administration (120 min) suggested selective nose-to-brain transport.,Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18525282/),min,120,127525,DB00747,Scopolamine
,24865285,relative bioavailability,The relative bioavailability of intranasal administrations was 51.8-70% when compared with subcutaneous injection.,"Microdialysis pharmacokinetic study of scopolamine in plasma, olfactory bulb and vestibule after intranasal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24865285/),%,51.8-70,128734,DB00747,Scopolamine
,24865285,drug target index (DTI),"Moreover, one can see that in comparison with scopolamine subcutaneous administration, scopolamine intranasal gel and solutions can increased drug target index (DTI) with olfactory bulb 1.69 and 2.05, vestibule 1.80 and 2.15, respectively.","Microdialysis pharmacokinetic study of scopolamine in plasma, olfactory bulb and vestibule after intranasal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24865285/),,1,128735,DB00747,Scopolamine
,24865285,drug target index (DTI),"Moreover, one can see that in comparison with scopolamine subcutaneous administration, scopolamine intranasal gel and solutions can increased drug target index (DTI) with olfactory bulb 1.69 and 2.05, vestibule 1.80 and 2.15, respectively.","Microdialysis pharmacokinetic study of scopolamine in plasma, olfactory bulb and vestibule after intranasal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24865285/),,2.05,128736,DB00747,Scopolamine
,24865285,drug target index (DTI),"Moreover, one can see that in comparison with scopolamine subcutaneous administration, scopolamine intranasal gel and solutions can increased drug target index (DTI) with olfactory bulb 1.69 and 2.05, vestibule 1.80 and 2.15, respectively.","Microdialysis pharmacokinetic study of scopolamine in plasma, olfactory bulb and vestibule after intranasal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24865285/),,2,128737,DB00747,Scopolamine
,18268929,trough FEV1,"Tiotropium 5 microg Respimat, 20 microg Respimat, and tiotropium 18 microg HandiHaler were statistically significantly higher than placebo for the primary endpoint (mean change in trough FEV1 was 150 mL (both Respimat doses) versus 20 mL (placebo Respimat); p < 0.05; and 230 mL (HandiHaler) versus -90 mL (placebo HandiHaler); p < or = 0.001).",A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18268929/),ml,150,130720,DB00747,Scopolamine
,18268929,trough FEV1,"Tiotropium 5 microg Respimat, 20 microg Respimat, and tiotropium 18 microg HandiHaler were statistically significantly higher than placebo for the primary endpoint (mean change in trough FEV1 was 150 mL (both Respimat doses) versus 20 mL (placebo Respimat); p < 0.05; and 230 mL (HandiHaler) versus -90 mL (placebo HandiHaler); p < or = 0.001).",A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18268929/),ml,20,130721,DB00747,Scopolamine
,18268929,trough FEV1,"Tiotropium 5 microg Respimat, 20 microg Respimat, and tiotropium 18 microg HandiHaler were statistically significantly higher than placebo for the primary endpoint (mean change in trough FEV1 was 150 mL (both Respimat doses) versus 20 mL (placebo Respimat); p < 0.05; and 230 mL (HandiHaler) versus -90 mL (placebo HandiHaler); p < or = 0.001).",A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18268929/),ml,230,130722,DB00747,Scopolamine
,31666152,time to maximal concentration (Tmax),"Intranasal administration can provide a time to maximal concentration (Tmax) of drugs (e.g., naloxone and midazolam) of 30 min or less.",Intranasal Scopolamine for Motion Sickness. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31666152/),min,30,131501,DB00747,Scopolamine
,31666152,Tmax,"Tmax was long for both dosages (High dose 75.0 ± 49.4 min, Low dose 61.9 ± 37.1 min), compared to other intranasally administered drugs and some previous studies with IN SCOP.",Intranasal Scopolamine for Motion Sickness. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31666152/),min,75.0,131502,DB00747,Scopolamine
,31666152,Tmax,"Tmax was long for both dosages (High dose 75.0 ± 49.4 min, Low dose 61.9 ± 37.1 min), compared to other intranasally administered drugs and some previous studies with IN SCOP.",Intranasal Scopolamine for Motion Sickness. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31666152/),min,61.9,131503,DB00747,Scopolamine
,16810649,m/,"The acquisition was performed in the multiple reaction monitoring (MRM) mode, by monitoring the transitions: m/z 357.9 > 103.1 for cimetropium and m/z 359.9 > 103.1 for butyl-scopolamine.",A rapid and sensitive liquid chromatography/positive ion tandem mass spectrometry method for the determination of cimetropium in human plasma by liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16810649/),,103.1,134214,DB00747,Scopolamine
>,16810649,m/z,"The acquisition was performed in the multiple reaction monitoring (MRM) mode, by monitoring the transitions: m/z 357.9 > 103.1 for cimetropium and m/z 359.9 > 103.1 for butyl-scopolamine.",A rapid and sensitive liquid chromatography/positive ion tandem mass spectrometry method for the determination of cimetropium in human plasma by liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16810649/),,103.1,134215,DB00747,Scopolamine
,16810649,total analysis time,"The results were linear over the studied range (0.2-100 ng ml(-1)), with r2 = 1.0000, and the total analysis time for each run was 2 min.",A rapid and sensitive liquid chromatography/positive ion tandem mass spectrometry method for the determination of cimetropium in human plasma by liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16810649/),min,2,134216,DB00747,Scopolamine
,16810649,recovery,The mean recovery ranged from 62.71 +/- 4.06 to 64.23 +/- 2.32%.,A rapid and sensitive liquid chromatography/positive ion tandem mass spectrometry method for the determination of cimetropium in human plasma by liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16810649/),%,62.71,134217,DB00747,Scopolamine
,16810649,recovery,The mean recovery ranged from 62.71 +/- 4.06 to 64.23 +/- 2.32%.,A rapid and sensitive liquid chromatography/positive ion tandem mass spectrometry method for the determination of cimetropium in human plasma by liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16810649/),%,64.23,134218,DB00747,Scopolamine
,33395621,IC50,"In particular, 3-methoxy-1-(4-(3-(pyrrolidin-1-yl)propoxy)phenyl)-pyridin-4(1H)-one (7i) demonstrated IC50 value of 0.52 nM in H3R antagonism and good selectivity over other histamine receptor subtypes.",Identification of N-phenyl-3-methoxy-4-pyridinones as orally bioavailable H3 receptor antagonists and β-amyloid aggregation inhibitors for the treatment of Alzheimer's disease. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33395621/),nM,0.52,135494,DB00747,Scopolamine
,19916374,constant flow rate,"The analytes were eluted at a constant flow rate of 0.45 mL/min; the mobile phase consisted of acetonitrile and a buffer of 5 mM ammonium acetate and 0.1% formic acid (60 + 40, v/v).",Validation of a liquid chromatographic/tandem mass spectrometric method for the determination of scopolamine butylbromide in human plasma: application of the method to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916374/),[ml] / [min],0.45,137244,DB00747,Scopolamine
>,19916374,m/z,"The mass spectrometer, equipped with an electrospray source in the positive ionization mode, was set up in the multiple-reaction monitoring mode to monitor the transitions m/z 360.6 > 102.5 (scopolamine butylbromide) and m/z 259.7 > 115.6 (propanolol).",Validation of a liquid chromatographic/tandem mass spectrometric method for the determination of scopolamine butylbromide in human plasma: application of the method to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916374/),,360.6,137245,DB00747,Scopolamine
>,19916374,m/z,"The mass spectrometer, equipped with an electrospray source in the positive ionization mode, was set up in the multiple-reaction monitoring mode to monitor the transitions m/z 360.6 > 102.5 (scopolamine butylbromide) and m/z 259.7 > 115.6 (propanolol).",Validation of a liquid chromatographic/tandem mass spectrometric method for the determination of scopolamine butylbromide in human plasma: application of the method to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916374/),,102.5,137246,DB00747,Scopolamine
>,19916374,m/z,"The mass spectrometer, equipped with an electrospray source in the positive ionization mode, was set up in the multiple-reaction monitoring mode to monitor the transitions m/z 360.6 > 102.5 (scopolamine butylbromide) and m/z 259.7 > 115.6 (propanolol).",Validation of a liquid chromatographic/tandem mass spectrometric method for the determination of scopolamine butylbromide in human plasma: application of the method to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916374/),,259.7,137247,DB00747,Scopolamine
>,19916374,m/z,"The mass spectrometer, equipped with an electrospray source in the positive ionization mode, was set up in the multiple-reaction monitoring mode to monitor the transitions m/z 360.6 > 102.5 (scopolamine butylbromide) and m/z 259.7 > 115.6 (propanolol).",Validation of a liquid chromatographic/tandem mass spectrometric method for the determination of scopolamine butylbromide in human plasma: application of the method to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916374/),,115.6,137248,DB00747,Scopolamine
,19916374,extraction recoveries,"The mean extraction recoveries of scopolamine butylbromide and propanolol from plasma were 69.00 and 80.76%, respectively.",Validation of a liquid chromatographic/tandem mass spectrometric method for the determination of scopolamine butylbromide in human plasma: application of the method to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916374/),%,69.00,137249,DB00747,Scopolamine
,19916374,extraction recoveries,"The mean extraction recoveries of scopolamine butylbromide and propanolol from plasma were 69.00 and 80.76%, respectively.",Validation of a liquid chromatographic/tandem mass spectrometric method for the determination of scopolamine butylbromide in human plasma: application of the method to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916374/),%,80.76,137250,DB00747,Scopolamine
,31642410,permeation flux,"The optimized nanoemulsion gel NEGT4 (droplet size 156.4 ±0.48 nm, with poly dispersity index 0.36 ±0.4, permeation flux 6.172±2.94 µg/cm2/h across rat skin) was prepared by spontaneous emulsification followed by sonication.","Design and Development of Novel Transdermal Nanoemulgel for Alzheimer's Disease: Pharmacokinetic, Pharmacodynamic and Biochemical Investigations. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31642410/),[μg] / [cm2·h],6.172,140511,DB00747,Scopolamine
,31642410,shelf life,NEGT4 was found to be non-irritant and possessed a shelf life of 4.11 years.,"Design and Development of Novel Transdermal Nanoemulgel for Alzheimer's Disease: Pharmacokinetic, Pharmacodynamic and Biochemical Investigations. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31642410/),years,4.11,140512,DB00747,Scopolamine
,17486675,run time,Reversed-phase chromatography of tiotropium and the internal standard clenbuterol was carried out using acetonitrile/10 mM ammonium acetate (1% formic acid) 40:60 as mobile phase in a run time of 3.0 min.,"Highly sensitive assay for tiotropium, a quaternary ammonium, in human plasma by high-performance liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17486675/),min,3.0,141842,DB00747,Scopolamine
,15792397,peak serum concentration (C(max)),"The mean peak serum concentration (C(max)) of 6.5 +/- 3.9 ng/ml (data in mean +/- SD) was attained after 15 +/- 3 minutes (t(max)), whereas in dialysate, a mean peak concentration of 2.7 +/- 1.7 ng/ml was measured after 27 +/- 8 minutes.",Pharmacokinetics of scopolamine in serum and subcutaneous adipose tissue in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792397/),[ng] / [ml],6.5,159525,DB00747,Scopolamine
,15792397,t(max),"The mean peak serum concentration (C(max)) of 6.5 +/- 3.9 ng/ml (data in mean +/- SD) was attained after 15 +/- 3 minutes (t(max)), whereas in dialysate, a mean peak concentration of 2.7 +/- 1.7 ng/ml was measured after 27 +/- 8 minutes.",Pharmacokinetics of scopolamine in serum and subcutaneous adipose tissue in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792397/),min,15,159526,DB00747,Scopolamine
,15792397,peak concentration,"The mean peak serum concentration (C(max)) of 6.5 +/- 3.9 ng/ml (data in mean +/- SD) was attained after 15 +/- 3 minutes (t(max)), whereas in dialysate, a mean peak concentration of 2.7 +/- 1.7 ng/ml was measured after 27 +/- 8 minutes.",Pharmacokinetics of scopolamine in serum and subcutaneous adipose tissue in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792397/),[ng] / [ml],2.7,159527,DB00747,Scopolamine
,15792397,elimination half-life,The elimination half-life of scopolamine was 121 +/- 85 minutes in serum and 166 +/- 117 minutes in dialysate.,Pharmacokinetics of scopolamine in serum and subcutaneous adipose tissue in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792397/),min,121,159528,DB00747,Scopolamine
,15792397,elimination half-life,The elimination half-life of scopolamine was 121 +/- 85 minutes in serum and 166 +/- 117 minutes in dialysate.,Pharmacokinetics of scopolamine in serum and subcutaneous adipose tissue in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792397/),min,166,159529,DB00747,Scopolamine
,15792397,total clearance,"Values for total clearance and volume of distribution in serum were 99.1 +/- 35.0 1/h and 188 +/- 76 1, respectively.",Pharmacokinetics of scopolamine in serum and subcutaneous adipose tissue in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792397/),[1] / [h],99.1,159530,DB00747,Scopolamine
,15792397,volume of distribution,"Values for total clearance and volume of distribution in serum were 99.1 +/- 35.0 1/h and 188 +/- 76 1, respectively.",Pharmacokinetics of scopolamine in serum and subcutaneous adipose tissue in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15792397/),1,188,159531,DB00747,Scopolamine
,2598990,Detection limits,Detection limits were 300 pg.,"Application of a radioreceptor assay in a pharmacokinetic study of oxitropium bromide in healthy volunteers after single i.v., oral and inhalation doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598990/),pg,300,161286,DB00747,Scopolamine
,2598990,Vc,"After i.v. administration the kinetic parameters were: Vc 38.41; t1/2 alpha 5.3 min; t1/2 beta 142 min; AUC 8.9 h.ng.ml-1; renal excretion 50.2%, k10 3.5 l.h-1 and total clearance 1874 ml/min.","Application of a radioreceptor assay in a pharmacokinetic study of oxitropium bromide in healthy volunteers after single i.v., oral and inhalation doses. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598990/),,38.41,161287,DB00747,Scopolamine
,2598990,t1/2 alpha,"After i.v. administration the kinetic parameters were: Vc 38.41; t1/2 alpha 5.3 min; t1/2 beta 142 min; AUC 8.9 h.ng.ml-1; renal excretion 50.2%, k10 3.5 l.h-1 and total clearance 1874 ml/min.","Application of a radioreceptor assay in a pharmacokinetic study of oxitropium bromide in healthy volunteers after single i.v., oral and inhalation doses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598990/),min,5.3,161288,DB00747,Scopolamine
,2598990,t1/2 beta,"After i.v. administration the kinetic parameters were: Vc 38.41; t1/2 alpha 5.3 min; t1/2 beta 142 min; AUC 8.9 h.ng.ml-1; renal excretion 50.2%, k10 3.5 l.h-1 and total clearance 1874 ml/min.","Application of a radioreceptor assay in a pharmacokinetic study of oxitropium bromide in healthy volunteers after single i.v., oral and inhalation doses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598990/),min,142,161289,DB00747,Scopolamine
,2598990,AUC,"After i.v. administration the kinetic parameters were: Vc 38.41; t1/2 alpha 5.3 min; t1/2 beta 142 min; AUC 8.9 h.ng.ml-1; renal excretion 50.2%, k10 3.5 l.h-1 and total clearance 1874 ml/min.","Application of a radioreceptor assay in a pharmacokinetic study of oxitropium bromide in healthy volunteers after single i.v., oral and inhalation doses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598990/),[h·ng] / [ml],8.9,161290,DB00747,Scopolamine
,2598990,renal excretion,"After i.v. administration the kinetic parameters were: Vc 38.41; t1/2 alpha 5.3 min; t1/2 beta 142 min; AUC 8.9 h.ng.ml-1; renal excretion 50.2%, k10 3.5 l.h-1 and total clearance 1874 ml/min.","Application of a radioreceptor assay in a pharmacokinetic study of oxitropium bromide in healthy volunteers after single i.v., oral and inhalation doses. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598990/),%,50.2,161291,DB00747,Scopolamine
,2598990,k10,"After i.v. administration the kinetic parameters were: Vc 38.41; t1/2 alpha 5.3 min; t1/2 beta 142 min; AUC 8.9 h.ng.ml-1; renal excretion 50.2%, k10 3.5 l.h-1 and total clearance 1874 ml/min.","Application of a radioreceptor assay in a pharmacokinetic study of oxitropium bromide in healthy volunteers after single i.v., oral and inhalation doses. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598990/),[l] / [h],3.5,161292,DB00747,Scopolamine
,2598990,total clearance,"After i.v. administration the kinetic parameters were: Vc 38.41; t1/2 alpha 5.3 min; t1/2 beta 142 min; AUC 8.9 h.ng.ml-1; renal excretion 50.2%, k10 3.5 l.h-1 and total clearance 1874 ml/min.","Application of a radioreceptor assay in a pharmacokinetic study of oxitropium bromide in healthy volunteers after single i.v., oral and inhalation doses. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598990/),[ml] / [min],1874,161293,DB00747,Scopolamine
,2598990,apparent bioavailabilities,"The apparent bioavailabilities were 0.48% and 12.4% by the oral and inhalation routes, respectively, based on the cumulative renal excretion.","Application of a radioreceptor assay in a pharmacokinetic study of oxitropium bromide in healthy volunteers after single i.v., oral and inhalation doses. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598990/),%,0.48,161294,DB00747,Scopolamine
,2598990,apparent bioavailabilities,"The apparent bioavailabilities were 0.48% and 12.4% by the oral and inhalation routes, respectively, based on the cumulative renal excretion.","Application of a radioreceptor assay in a pharmacokinetic study of oxitropium bromide in healthy volunteers after single i.v., oral and inhalation doses. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598990/),%,12.4,161295,DB00747,Scopolamine
,11748515,effect-site concentrations,"Sufentanil was administered by target-controlled infusion, with target effect-site concentrations ranging from 0.4 to 4.5 ng/mL.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[ng] / [ml],0.4 to 4.5,161310,DB00747,Scopolamine
,11748515,V(1),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,5.7,161311,DB00747,Scopolamine
,11748515,V(2),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,18.1,161312,DB00747,Scopolamine
,11748515,V(3),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,225,161313,DB00747,Scopolamine
,11748515,Cl(1),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],0.69,161314,DB00747,Scopolamine
,11748515,Cl(2),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],3.1,161315,DB00747,Scopolamine
,11748515,Cl(3),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],1.4,161316,DB00747,Scopolamine
,31298070,IC50,"DPZ and its three metabolites demonstrated anti-AchE activities with the IC50 in the order of DPZ (7.20 × 10-2 μM), 6-DDPZ (1.14 × 10-1 μM), 5-DDPZ (4.03 × 10-1 μM) and DPZ N-oxide (1.61 μM).",Reduced systemic exposure and brain uptake of donepezil in rats with scopolamine-induced cognitive impairment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298070/),μM,7.20 × 10-2,168520,DB00747,Scopolamine
,31298070,IC50,"DPZ and its three metabolites demonstrated anti-AchE activities with the IC50 in the order of DPZ (7.20 × 10-2 μM), 6-DDPZ (1.14 × 10-1 μM), 5-DDPZ (4.03 × 10-1 μM) and DPZ N-oxide (1.61 μM).",Reduced systemic exposure and brain uptake of donepezil in rats with scopolamine-induced cognitive impairment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298070/),μM,1.14 × 10-1,168521,DB00747,Scopolamine
,31298070,IC50,"DPZ and its three metabolites demonstrated anti-AchE activities with the IC50 in the order of DPZ (7.20 × 10-2 μM), 6-DDPZ (1.14 × 10-1 μM), 5-DDPZ (4.03 × 10-1 μM) and DPZ N-oxide (1.61 μM).",Reduced systemic exposure and brain uptake of donepezil in rats with scopolamine-induced cognitive impairment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298070/),μM,4.03 × 10-1,168522,DB00747,Scopolamine
,31298070,IC50,"DPZ and its three metabolites demonstrated anti-AchE activities with the IC50 in the order of DPZ (7.20 × 10-2 μM), 6-DDPZ (1.14 × 10-1 μM), 5-DDPZ (4.03 × 10-1 μM) and DPZ N-oxide (1.61 μM).",Reduced systemic exposure and brain uptake of donepezil in rats with scopolamine-induced cognitive impairment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298070/),μM,1.61,168523,DB00747,Scopolamine
,14606931,oral bioavailability,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,10,171113,DB00747,Scopolamine
,14606931,oral bioavailability,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,74,171114,DB00747,Scopolamine
,14606931,oral bioavailability,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,33,171115,DB00747,Scopolamine
,14606931,bioavailabilities,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,26,171116,DB00747,Scopolamine
,14606931,bioavailabilities,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,91,171117,DB00747,Scopolamine
,14606931,Terminal disposition half-lives,"Terminal disposition half-lives of tolterodine and 5-hydroxymethyl-tolterodine (in CYP2D6 extensive metabolisers) are 2-3 and 3-4 hours, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),h,2-3,171118,DB00747,Scopolamine
,14606931,Terminal disposition half-lives,"Terminal disposition half-lives of tolterodine and 5-hydroxymethyl-tolterodine (in CYP2D6 extensive metabolisers) are 2-3 and 3-4 hours, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),h,3-4,171119,DB00747,Scopolamine
,16719539,constant rate,The remainder is released at a constant rate of approximately 5 microg/hour.,Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16719539/),[μg] / [h],5,174190,DB00747,Scopolamine
,16719539,steady state,TTS-S attains that concentration after 6 hours; a steady state of about 100 pg/mL is achieved 8-12 hours after application.,Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16719539/),[pg] / [ml],100,174191,DB00747,Scopolamine
,1874209,maximum levels,"The maximum levels of plasma hyoscine (6.6 micrograms l-1) and morphine (158 micrograms l-1) and the time they were reached (13.0 and 9.7 min, respectively) were comparable with the values obtained in earlier studies using young healthy subjects.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),[μg] / [l],6.6,178377,DB00747,Scopolamine
,1874209,maximum levels,"The maximum levels of plasma hyoscine (6.6 micrograms l-1) and morphine (158 micrograms l-1) and the time they were reached (13.0 and 9.7 min, respectively) were comparable with the values obtained in earlier studies using young healthy subjects.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),[μg] / [l],158,178378,DB00747,Scopolamine
,1874209,maximum levels,"The maximum levels of plasma hyoscine (6.6 micrograms l-1) and morphine (158 micrograms l-1) and the time they were reached (13.0 and 9.7 min, respectively) were comparable with the values obtained in earlier studies using young healthy subjects.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),min,13.0,178379,DB00747,Scopolamine
,1874209,maximum levels,"The maximum levels of plasma hyoscine (6.6 micrograms l-1) and morphine (158 micrograms l-1) and the time they were reached (13.0 and 9.7 min, respectively) were comparable with the values obtained in earlier studies using young healthy subjects.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),min,9.7,178380,DB00747,Scopolamine
,1874209,time,"The maximum levels of plasma hyoscine (6.6 micrograms l-1) and morphine (158 micrograms l-1) and the time they were reached (13.0 and 9.7 min, respectively) were comparable with the values obtained in earlier studies using young healthy subjects.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),min,13.0,178381,DB00747,Scopolamine
,1874209,time,"The maximum levels of plasma hyoscine (6.6 micrograms l-1) and morphine (158 micrograms l-1) and the time they were reached (13.0 and 9.7 min, respectively) were comparable with the values obtained in earlier studies using young healthy subjects.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),min,9.7,178382,DB00747,Scopolamine
,1874209,elimination half-life,"The elimination half-life of hyoscine in the plasma was 2.4 h, which is somewhat greater than obtained in earlier studies with young healthy patients under regional anaesthesia.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),h,2.4,178383,DB00747,Scopolamine
,1874209,t1/2el,Elimination of plasma morphine (t1/2el = 3.3 h) was not significantly altered by the procedure.,Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),h,3.3,178384,DB00747,Scopolamine
,8863287,Times to reach maximum effect,"Times to reach maximum effect were 1.05 and 0.27 h after i.n. and i.v. dosage, respectively.",Bioavailability of intranasal scopolamine in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863287/),h,1.05,185951,DB00747,Scopolamine
,8863287,Times to reach maximum effect,"Times to reach maximum effect were 1.05 and 0.27 h after i.n. and i.v. dosage, respectively.",Bioavailability of intranasal scopolamine in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863287/),h,0.27,185952,DB00747,Scopolamine
,8863287,Absolute intranasal bioavailability,"Absolute intranasal bioavailability, calculated from the area under the drug concentration vs time curve, was found to be significantly greater than that of p.o. scopolamine (83% vs 3.7%, p < 0.05).",Bioavailability of intranasal scopolamine in normal subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863287/),%,83,185953,DB00747,Scopolamine
,8863287,Absolute intranasal bioavailability,"Absolute intranasal bioavailability, calculated from the area under the drug concentration vs time curve, was found to be significantly greater than that of p.o. scopolamine (83% vs 3.7%, p < 0.05).",Bioavailability of intranasal scopolamine in normal subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863287/),%,3.7,185954,DB00747,Scopolamine
,25161072,C,"Patients with CF aged 5 to 11, 12 to 17, and ≥ 18 years had similar tiotropium plasma concentrations (geometric mean C(0.083,ss,norm): 2.22 pg/mL/μg; not determined for patients aged <5 years).",Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25161072/),[pg] / [ml·μg],2.22,198500,DB00747,Scopolamine
,25161072,"fe(0-4,ss)","The fraction excreted unchanged in the urine was 3.4-fold lower for patients aged 0.4 to <5 years than for those aged 5 to 11 years (fe(0-4,ss): 1.19% vs 4.09%).",Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25161072/),%,1.19,198501,DB00747,Scopolamine
,25161072,"fe(0-4,ss)","The fraction excreted unchanged in the urine was 3.4-fold lower for patients aged 0.4 to <5 years than for those aged 5 to 11 years (fe(0-4,ss): 1.19% vs 4.09%).",Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25161072/),%,4.09,198502,DB00747,Scopolamine
,34086100,Tmax,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),min,5,204525,DB00747,Scopolamine
,34086100,Cmax,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,1489.5,204526,DB00747,Scopolamine
,34086100,systemic bioavailability (F,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,118.65,204527,DB00747,Scopolamine
,34086100,AUC,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,"35,921.75",204528,DB00747,Scopolamine
,34086100,half-life,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),min,30.92,204529,DB00747,Scopolamine
,34086100,Tmax,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),min,15,204530,DB00747,Scopolamine
,34086100,Cmax,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,56.29,204531,DB00747,Scopolamine
,34086100,F,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,4.39,204532,DB00747,Scopolamine
,34086100,AUC,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,1663.79,204533,DB00747,Scopolamine
,34086100,t1/2,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,13.48,204534,DB00747,Scopolamine
,34086100,Kel (,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),[1] / [min],0.0514,204535,DB00747,Scopolamine
,7446137,recovery,"The recovery of atropine was near 100% when the drug was added at different concentrations to normal, pooled human plasma.",Radioimmunoassay for atropine and l-hyoscyamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7446137/),%,100,208739,DB00747,Scopolamine
,7446137,t 1/2,A biexponential serum decay curve was demonstrated in both cases with a very rapid distribution phase (t 1/2 0.63 and 1.38 min.) and a much slower elimination phase (t 1/2 1.86 and 2.09 hrs.).,Radioimmunoassay for atropine and l-hyoscyamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7446137/),min,0.63,208740,DB00747,Scopolamine
,7446137,t 1/2,A biexponential serum decay curve was demonstrated in both cases with a very rapid distribution phase (t 1/2 0.63 and 1.38 min.) and a much slower elimination phase (t 1/2 1.86 and 2.09 hrs.).,Radioimmunoassay for atropine and l-hyoscyamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7446137/),min,1.38,208741,DB00747,Scopolamine
,7446137,t 1/2,A biexponential serum decay curve was demonstrated in both cases with a very rapid distribution phase (t 1/2 0.63 and 1.38 min.) and a much slower elimination phase (t 1/2 1.86 and 2.09 hrs.).,Radioimmunoassay for atropine and l-hyoscyamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7446137/),h,1.86,208742,DB00747,Scopolamine
,7446137,t 1/2,A biexponential serum decay curve was demonstrated in both cases with a very rapid distribution phase (t 1/2 0.63 and 1.38 min.) and a much slower elimination phase (t 1/2 1.86 and 2.09 hrs.).,Radioimmunoassay for atropine and l-hyoscyamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7446137/),h,2.09,208743,DB00747,Scopolamine
,30077712,IC50,"Both d-VAS and l-VAS were exhibited promising acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities, and the BChE inhibitory activity of d-VAS with IC50 of 0.03 ± 0.001 μM was significantly stronger than that of l-VAS with IC50 of 0.98 ± 0.19 μM.","Stereoselective glucuronidation metabolism, pharmacokinetics, anti-amnesic pharmacodynamics, and toxic properties of vasicine enantiomers in vitro and in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077712/),μM,0.03,209813,DB00747,Scopolamine
,30077712,IC50,"Both d-VAS and l-VAS were exhibited promising acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities, and the BChE inhibitory activity of d-VAS with IC50 of 0.03 ± 0.001 μM was significantly stronger than that of l-VAS with IC50 of 0.98 ± 0.19 μM.","Stereoselective glucuronidation metabolism, pharmacokinetics, anti-amnesic pharmacodynamics, and toxic properties of vasicine enantiomers in vitro and in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077712/),μM,0.98,209814,DB00747,Scopolamine
,30077712,LD50,"In addition, the LD50 value of d-VAS (282.51 mg·kg-1) was slight lower than l-VAS (319.75 mg·kg-1).","Stereoselective glucuronidation metabolism, pharmacokinetics, anti-amnesic pharmacodynamics, and toxic properties of vasicine enantiomers in vitro and in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077712/),[mg] / [kg],282.51,209815,DB00747,Scopolamine
,30077712,LD50,"In addition, the LD50 value of d-VAS (282.51 mg·kg-1) was slight lower than l-VAS (319.75 mg·kg-1).","Stereoselective glucuronidation metabolism, pharmacokinetics, anti-amnesic pharmacodynamics, and toxic properties of vasicine enantiomers in vitro and in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30077712/),[mg] / [kg],319.75,209816,DB00747,Scopolamine
,2800990,apparent elimination phase half-life,The apparent elimination phase half-life of scopolamine in serum was only around 1 h.,Pharmacokinetics of scopolamine during caesarean section: relationship between serum concentration and effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2800990/),h,1,210036,DB00747,Scopolamine
,32300962,release rate,"In residual drug analyses, mean ± SD scopolamine release rate was 0.015 ± 0.002 mg/h (11% RSD), vs. 0.016 ± 0.006 mg/h (35% RSD) from numeric deconvolution, 0.015 ± 0.005 mg/h (34% RSD) from graphical analysis, and 0.015 ± 0.007 mg/h (44% RSD) from non-compartmental analysis.",Determination of Rate and Extent of Scopolamine Release from Transderm Scōp® Transdermal Drug Delivery Systems in Healthy Human Adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32300962/),[mg] / [h],0.015,210291,DB00747,Scopolamine
,32300962,release rate,"In residual drug analyses, mean ± SD scopolamine release rate was 0.015 ± 0.002 mg/h (11% RSD), vs. 0.016 ± 0.006 mg/h (35% RSD) from numeric deconvolution, 0.015 ± 0.005 mg/h (34% RSD) from graphical analysis, and 0.015 ± 0.007 mg/h (44% RSD) from non-compartmental analysis.",Determination of Rate and Extent of Scopolamine Release from Transderm Scōp® Transdermal Drug Delivery Systems in Healthy Human Adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32300962/),[mg] / [h],0.016,210292,DB00747,Scopolamine
,32300962,release rate,"In residual drug analyses, mean ± SD scopolamine release rate was 0.015 ± 0.002 mg/h (11% RSD), vs. 0.016 ± 0.006 mg/h (35% RSD) from numeric deconvolution, 0.015 ± 0.005 mg/h (34% RSD) from graphical analysis, and 0.015 ± 0.007 mg/h (44% RSD) from non-compartmental analysis.",Determination of Rate and Extent of Scopolamine Release from Transderm Scōp® Transdermal Drug Delivery Systems in Healthy Human Adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32300962/),[mg] / [h],0.015,210293,DB00747,Scopolamine
,32300962,release rate,"In residual drug analyses, mean ± SD scopolamine release rate was 0.015 ± 0.002 mg/h (11% RSD), vs. 0.016 ± 0.006 mg/h (35% RSD) from numeric deconvolution, 0.015 ± 0.005 mg/h (34% RSD) from graphical analysis, and 0.015 ± 0.007 mg/h (44% RSD) from non-compartmental analysis.",Determination of Rate and Extent of Scopolamine Release from Transderm Scōp® Transdermal Drug Delivery Systems in Healthy Human Adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32300962/),[mg] / [h],0.015,210294,DB00747,Scopolamine
,32300962,total drug released,"In residual drug analyses, total drug released was 1.09 ± 0.11 mg (10% RSD), vs. 1.12 ± 0.40 mg (35% RSD) from numeric deconvolution, 1.07 ± 0.35 mg (33% RSD) from graphical analysis, and 1.07 ± 0.45 (42% RSD) from non-compartmental analysis.",Determination of Rate and Extent of Scopolamine Release from Transderm Scōp® Transdermal Drug Delivery Systems in Healthy Human Adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32300962/),mg,1.09,210295,DB00747,Scopolamine
,32300962,total drug released,"In residual drug analyses, total drug released was 1.09 ± 0.11 mg (10% RSD), vs. 1.12 ± 0.40 mg (35% RSD) from numeric deconvolution, 1.07 ± 0.35 mg (33% RSD) from graphical analysis, and 1.07 ± 0.45 (42% RSD) from non-compartmental analysis.",Determination of Rate and Extent of Scopolamine Release from Transderm Scōp® Transdermal Drug Delivery Systems in Healthy Human Adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32300962/),mg,1.12,210296,DB00747,Scopolamine
,32300962,total drug released,"In residual drug analyses, total drug released was 1.09 ± 0.11 mg (10% RSD), vs. 1.12 ± 0.40 mg (35% RSD) from numeric deconvolution, 1.07 ± 0.35 mg (33% RSD) from graphical analysis, and 1.07 ± 0.45 (42% RSD) from non-compartmental analysis.",Determination of Rate and Extent of Scopolamine Release from Transderm Scōp® Transdermal Drug Delivery Systems in Healthy Human Adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32300962/),mg,1.07,210297,DB00747,Scopolamine
,32300962,total drug released,"In residual drug analyses, total drug released was 1.09 ± 0.11 mg (10% RSD), vs. 1.12 ± 0.40 mg (35% RSD) from numeric deconvolution, 1.07 ± 0.35 mg (33% RSD) from graphical analysis, and 1.07 ± 0.45 (42% RSD) from non-compartmental analysis.",Determination of Rate and Extent of Scopolamine Release from Transderm Scōp® Transdermal Drug Delivery Systems in Healthy Human Adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32300962/),,1.07,210298,DB00747,Scopolamine
,34173038,retention times,"After a simple protein precipitation step, samples are separated on 2-μm C18 column kept at 40 °C, using isocratic flow of 80% methanol in pH 9.5 ammonium formate buffer, and retention times were about 1.8 and 2.9 min for galantamine and nalbuphine, respectively.",LC-MS bioanalysis of targeted nasal galantamine bound chitosan nanoparticles in rats' brain homogenate and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34173038/),min,1.8,210869,DB00747,Scopolamine
,34173038,retention times,"After a simple protein precipitation step, samples are separated on 2-μm C18 column kept at 40 °C, using isocratic flow of 80% methanol in pH 9.5 ammonium formate buffer, and retention times were about 1.8 and 2.9 min for galantamine and nalbuphine, respectively.",LC-MS bioanalysis of targeted nasal galantamine bound chitosan nanoparticles in rats' brain homogenate and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34173038/),min,2.9,210870,DB00747,Scopolamine
,11028944,Cmax,"Following administration of a 0.2 mg dose, the average Cmax values were found to be 262+/-118, 419+/-161, and 488+/-331 pg/ mL for pH 4.0, 7.0, and 9.0 formulations, respectively.",Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028944/),[pg] / [ml],262,217371,DB00747,Scopolamine
,11028944,Cmax,"Following administration of a 0.2 mg dose, the average Cmax values were found to be 262+/-118, 419+/-161, and 488+/-331 pg/ mL for pH 4.0, 7.0, and 9.0 formulations, respectively.",Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028944/),[pg] / [ml],419,217372,DB00747,Scopolamine
,11028944,Cmax,"Following administration of a 0.2 mg dose, the average Cmax values were found to be 262+/-118, 419+/-161, and 488+/-331 pg/ mL for pH 4.0, 7.0, and 9.0 formulations, respectively.",Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028944/),[pg] / [ml],488,217373,DB00747,Scopolamine
,11028944,Cmax,"At the 0.4 mg dose the average Cmax values were found to be 503+/-199, 933+/-449, and 1,308+/-473 pg/mL for pH 4.0, 7.0, and 9.0 formulations, respectively.",Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028944/),[pg] / [ml],503,217374,DB00747,Scopolamine
,11028944,Cmax,"At the 0.4 mg dose the average Cmax values were found to be 503+/-199, 933+/-449, and 1,308+/-473 pg/mL for pH 4.0, 7.0, and 9.0 formulations, respectively.",Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028944/),[pg] / [ml],933,217375,DB00747,Scopolamine
,11028944,Cmax,"At the 0.4 mg dose the average Cmax values were found to be 503+/-199, 933+/-449, and 1,308+/-473 pg/mL for pH 4.0, 7.0, and 9.0 formulations, respectively.",Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028944/),[pg] / [ml],"1,308",217376,DB00747,Scopolamine
,11028944,AUC,"At a 0.2 mg dose, the AUC values were found to be 23,208+/-6,824, 29,145+/-9,225, and 25,721+/-5,294 pg x min/mL for formulation pH 4.0, 7.0, and 9.0, respectively.",Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028944/),[min·pg] / [ml],"23,208",217377,DB00747,Scopolamine
,11028944,AUC,"At a 0.2 mg dose, the AUC values were found to be 23,208+/-6,824, 29,145+/-9,225, and 25,721+/-5,294 pg x min/mL for formulation pH 4.0, 7.0, and 9.0, respectively.",Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028944/),[min·pg] / [ml],"29,145",217378,DB00747,Scopolamine
,11028944,AUC,"At a 0.2 mg dose, the AUC values were found to be 23,208+/-6,824, 29,145+/-9,225, and 25,721+/-5,294 pg x min/mL for formulation pH 4.0, 7.0, and 9.0, respectively.",Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028944/),[min·pg] / [ml],"25,721",217379,DB00747,Scopolamine
,11028944,AUC,"At a 0.4 mg dose, the average AUC value was found to be high for pH 9.0 formulation (70,740+/-29,381 pg x min/mL) as compared to those of pH 4.0 (59,573+/-13,700 pg x min/mL) and pH 7.0 (55,298+/-17,305 pg x min/mL) formulations.",Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028944/),[min·pg] / [ml],"70,740",217380,DB00747,Scopolamine
,11028944,AUC,"At a 0.4 mg dose, the average AUC value was found to be high for pH 9.0 formulation (70,740+/-29,381 pg x min/mL) as compared to those of pH 4.0 (59,573+/-13,700 pg x min/mL) and pH 7.0 (55,298+/-17,305 pg x min/mL) formulations.",Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028944/),[min·pg] / [ml],"59,573",217381,DB00747,Scopolamine
,11028944,AUC,"At a 0.4 mg dose, the average AUC value was found to be high for pH 9.0 formulation (70,740+/-29,381 pg x min/mL) as compared to those of pH 4.0 (59,573+/-13,700 pg x min/mL) and pH 7.0 (55,298+/-17,305 pg x min/mL) formulations.",Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028944/),[min·pg] / [ml],"55,298",217382,DB00747,Scopolamine
,11028944,Tmax,"For example, at a 0.4 mg dose, the average Tmax values were 26.7+/-5.8, 15.0+/-10.0, and 8.8+/-2.5 minutes at formulation pH 4.0, 7.0, and 9.0, respectively.",Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028944/),min,26.7,217383,DB00747,Scopolamine
,11028944,Tmax,"For example, at a 0.4 mg dose, the average Tmax values were 26.7+/-5.8, 15.0+/-10.0, and 8.8+/-2.5 minutes at formulation pH 4.0, 7.0, and 9.0, respectively.",Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028944/),min,15.0,217384,DB00747,Scopolamine
,11028944,Tmax,"For example, at a 0.4 mg dose, the average Tmax values were 26.7+/-5.8, 15.0+/-10.0, and 8.8+/-2.5 minutes at formulation pH 4.0, 7.0, and 9.0, respectively.",Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028944/),min,8.8,217385,DB00747,Scopolamine
,21906629,T(1/2),"This analysis revealed a rapid increase of the plasma concentration, peaking within 30min after administration with a T(1/2) of approximately 30min and a peak plasma concentration of about 2μM.",Cognitive enhancing effects of an AMPA receptor positive modulator on place learning in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21906629/),min,30,217699,DB00747,Scopolamine
,21906629,peak plasma concentration,"This analysis revealed a rapid increase of the plasma concentration, peaking within 30min after administration with a T(1/2) of approximately 30min and a peak plasma concentration of about 2μM.",Cognitive enhancing effects of an AMPA receptor positive modulator on place learning in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21906629/),μM,2,217700,DB00747,Scopolamine
,3761170,terminal half-life,"After intravenous administration, the plasma levels and urinary excretion indicated that the drug is distributed and eliminated at a rapid rate (terminal half-life, 50 +/- 8 min) and that urinary excretion is not the exclusive route of elimination (46 +/- 2%) of the administered dose).","Discontinuous oral absorption of cimetropium bromide, a new antispasmodic drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3761170/),min,50,218610,DB00747,Scopolamine
,4039166,Biliary excretion,Biliary excretion of the rat is 12% after oral and 14% after intravenous administration.,[Biochemical studies with oxitropium bromide. 1. Pharmacokinetics and metabolism in the rat and dog]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039166/),%,12,220662,DB00747,Scopolamine
,4039166,Biliary excretion,Biliary excretion of the rat is 12% after oral and 14% after intravenous administration.,[Biochemical studies with oxitropium bromide. 1. Pharmacokinetics and metabolism in the rat and dog]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039166/),%,14,220663,DB00747,Scopolamine
,11097144,Cmax,The Cmax value (6.61+/-0.63 ng/ml) of scopolamine after i.v. administration in male subjects was significant higher compared with the value in female subjects (3.93+/-0.04 ng/ml; geometric mean +/- SEM; p = 0.007).,Influence of grapefruit juice on scopolamine pharmacokinetics and pharmacodynamics in healthy male and female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097144/),[ng] / [ml],6.61,222186,DB00747,Scopolamine
,11097144,Cmax,The Cmax value (6.61+/-0.63 ng/ml) of scopolamine after i.v. administration in male subjects was significant higher compared with the value in female subjects (3.93+/-0.04 ng/ml; geometric mean +/- SEM; p = 0.007).,Influence of grapefruit juice on scopolamine pharmacokinetics and pharmacodynamics in healthy male and female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11097144/),[ng] / [ml],3.93,222187,DB00747,Scopolamine
,17005916,Ki,"On the stimulation of guanosine 5'-O-(3-[35S]thio)triphosphate binding to this receptor, BF2.649 behaved as a competitive antagonist with a Ki value of 0.16 nM and as an inverse agonist with an EC50 value of 1.5 nM and an intrinsic activity approximately 50% higher than that of ciproxifan.","BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17005916/),nM,0.16,231886,DB00747,Scopolamine
,17005916,EC50,"On the stimulation of guanosine 5'-O-(3-[35S]thio)triphosphate binding to this receptor, BF2.649 behaved as a competitive antagonist with a Ki value of 0.16 nM and as an inverse agonist with an EC50 value of 1.5 nM and an intrinsic activity approximately 50% higher than that of ciproxifan.","BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17005916/),nM,1.5,231887,DB00747,Scopolamine
,17005916,oral bioavailability coefficient,"In mice, the oral bioavailability coefficient, i.e., the ratio of plasma areas under the curve after oral and i.v. administrations, respectively, was 84%.","BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17005916/),%,84,231888,DB00747,Scopolamine
,17005916,ED50,"BF2.649 dose dependently enhanced tele-methylhistamine levels in mouse brain, an index of histaminergic neuron activity, with an ED50 value of 1.6 mg/kg p.o., a response that persisted after repeated administrations for 17 days.","BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17005916/),[mg] / [kg],1.6,231889,DB00747,Scopolamine
,4039167,t 1/2,"The concentrations of radioactivity measured in the plasma after i.v. administration show a biphasic course, a rapid alpha phase and a terminal phase (t 1/2 = 1.5 h).",[Biochemical studies with oxitropium bromide. 2. Pharmacokinetics and metabolism in humans]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039167/),h,1.5,239635,DB00747,Scopolamine
,4039167,cumulative renal excretion,"The cumulative renal excretion of the radioactivity is 68-78% for i.v. administration, 13% for oral administration, and 10% for inhalation.",[Biochemical studies with oxitropium bromide. 2. Pharmacokinetics and metabolism in humans]. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039167/),%,68-78,239636,DB00747,Scopolamine
,4039167,cumulative renal excretion,"The cumulative renal excretion of the radioactivity is 68-78% for i.v. administration, 13% for oral administration, and 10% for inhalation.",[Biochemical studies with oxitropium bromide. 2. Pharmacokinetics and metabolism in humans]. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039167/),%,13,239637,DB00747,Scopolamine
,4039167,cumulative renal excretion,"The cumulative renal excretion of the radioactivity is 68-78% for i.v. administration, 13% for oral administration, and 10% for inhalation.",[Biochemical studies with oxitropium bromide. 2. Pharmacokinetics and metabolism in humans]. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039167/),%,10,239638,DB00747,Scopolamine
,33658313,pEC50,Respective pEC50 values were 7.06 and 4.97.,Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33658313/),,7.06,243489,DB00747,Scopolamine
,33658313,pEC50,Respective pEC50 values were 7.06 and 4.97.,Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33658313/),,4.97,243490,DB00747,Scopolamine
,10984366,peak ex,"A randomized, single-blind, placebo-controlled study was performed in 74 patients between 18 and 55 years old presenting to the emergency department (ED) for treatment of acute asthma with a peak expiratory flow (PEF) of 50% or less than the normal predicted value.",Efficacy of adding multiple doses of oxitropium bromide to salbutamol delivered by means of a metered-dose inhaler with a spacer device in adults with acute severe asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984366/),%,50,246128,DB00747,Scopolamine
,16179215,FE,"After 12 weeks, the average post-dose FEV1 over 12 h was significantly higher with tiotropium compared with salmeterol (167 vs. 130 mL, respectively, p=0.03), as was peak FEV1 (262 vs. 216 ml, respectively, p=0.01).",Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16179215/),ml,167,246316,DB00747,Scopolamine
,16179215,FE,"After 12 weeks, the average post-dose FEV1 over 12 h was significantly higher with tiotropium compared with salmeterol (167 vs. 130 mL, respectively, p=0.03), as was peak FEV1 (262 vs. 216 ml, respectively, p=0.01).",Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16179215/),ml,130,246317,DB00747,Scopolamine
,16179215,peak FEV1,"After 12 weeks, the average post-dose FEV1 over 12 h was significantly higher with tiotropium compared with salmeterol (167 vs. 130 mL, respectively, p=0.03), as was peak FEV1 (262 vs. 216 ml, respectively, p=0.01).",Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16179215/),ml,262,246318,DB00747,Scopolamine
,16179215,peak FEV1,"After 12 weeks, the average post-dose FEV1 over 12 h was significantly higher with tiotropium compared with salmeterol (167 vs. 130 mL, respectively, p=0.03), as was peak FEV1 (262 vs. 216 ml, respectively, p=0.01).",Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16179215/),ml,216,246319,DB00747,Scopolamine
,11144994,clearance (CL),"The values of the pharmacokinetic parameters of scopolamine after i.v. infusion were clearance (CL) 205 +/- 36.6 L/h, volume of distribution (Vd) 363 +/- 66.7 L, distribution half-life (t1/2 alpha) 2.9 +/- 0.67 min, and terminal half-life (t1/2 beta) 105.4 +/- 9.94 min (mean +/- SEM).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144994/),[l] / [h],205,246986,DB00747,Scopolamine
,11144994,volume of distribution (Vd),"The values of the pharmacokinetic parameters of scopolamine after i.v. infusion were clearance (CL) 205 +/- 36.6 L/h, volume of distribution (Vd) 363 +/- 66.7 L, distribution half-life (t1/2 alpha) 2.9 +/- 0.67 min, and terminal half-life (t1/2 beta) 105.4 +/- 9.94 min (mean +/- SEM).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144994/),l,363,246987,DB00747,Scopolamine
,11144994,distribution half-life (t1/2 alpha),"The values of the pharmacokinetic parameters of scopolamine after i.v. infusion were clearance (CL) 205 +/- 36.6 L/h, volume of distribution (Vd) 363 +/- 66.7 L, distribution half-life (t1/2 alpha) 2.9 +/- 0.67 min, and terminal half-life (t1/2 beta) 105.4 +/- 9.94 min (mean +/- SEM).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144994/),min,2.9,246988,DB00747,Scopolamine
,11144994,terminal half-life (t1/2 beta),"The values of the pharmacokinetic parameters of scopolamine after i.v. infusion were clearance (CL) 205 +/- 36.6 L/h, volume of distribution (Vd) 363 +/- 66.7 L, distribution half-life (t1/2 alpha) 2.9 +/- 0.67 min, and terminal half-life (t1/2 beta) 105.4 +/- 9.94 min (mean +/- SEM).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144994/),min,105.4,246989,DB00747,Scopolamine
,11144994,peak serum concentrations (Cmax),"Mean peak serum concentrations (Cmax) were 4.66 and 0.96 ng/ml after i.v. and i.m. administration, respectively (p < 0.05).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144994/),[ng] / [ml],4.66,246990,DB00747,Scopolamine
,11144994,peak serum concentrations (Cmax),"Mean peak serum concentrations (Cmax) were 4.66 and 0.96 ng/ml after i.v. and i.m. administration, respectively (p < 0.05).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144994/),[ng] / [ml],0.96,246991,DB00747,Scopolamine
,11144994,area under the serum concentration versus time curve (AUC),"The area under the serum concentration versus time curve (AUC) after i.m. administration (81.27 +/- 11.21 ng/ml/min) was significantly lower compared to the value after i.v. infusion (157.28 +/- 30.86 ng/ml/min) (mean +/- SEM, p < 0.05).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144994/),[ng] / [min·ml],81.27,246992,DB00747,Scopolamine
,11144994,area under the serum concentration versus time curve (AUC),"The area under the serum concentration versus time curve (AUC) after i.m. administration (81.27 +/- 11.21 ng/ml/min) was significantly lower compared to the value after i.v. infusion (157.28 +/- 30.86 ng/ml/min) (mean +/- SEM, p < 0.05).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144994/),[ng] / [min·ml],157.28,246993,DB00747,Scopolamine
,11144994,Absolute bioavailability,Absolute bioavailability of scopolamine after i.m. injection was 57% +/- 0.08% (mean +/- SEM).,Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144994/),%,57,246994,DB00747,Scopolamine
,11144994,E0,"The averaged values of the pharmacodynamic parameters were E0 = 0.58 microV2, Emax = 0.29 microV2, EC50 = 0.60 ng/ml, and gamma = 1.17.",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144994/),μv2,0.58,246995,DB00747,Scopolamine
,11144994,Emax,"The averaged values of the pharmacodynamic parameters were E0 = 0.58 microV2, Emax = 0.29 microV2, EC50 = 0.60 ng/ml, and gamma = 1.17.",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144994/),μv2,0.29,246996,DB00747,Scopolamine
,11144994,EC50,"The averaged values of the pharmacodynamic parameters were E0 = 0.58 microV2, Emax = 0.29 microV2, EC50 = 0.60 ng/ml, and gamma = 1.17.",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144994/),[ng] / [ml],0.60,246997,DB00747,Scopolamine
,11144994,gamma,"The averaged values of the pharmacodynamic parameters were E0 = 0.58 microV2, Emax = 0.29 microV2, EC50 = 0.60 ng/ml, and gamma = 1.17.",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144994/),,1.17,246998,DB00747,Scopolamine
,8852700,IC50,"At 200 pmol/l [3H]NMS, IC50 was 1.4 +/- 0.1 x 10(-9) M atropine (CV = 8.1%).",Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet combination autoinjectors containing HI 6 or HLö 7. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852700/),M,1.4,247909,DB00747,Scopolamine
,8852700,absorption half-time,The atropine absorption half-time (7 min) was not affected either by the autoinjector type or by the combination with oximes.,Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet combination autoinjectors containing HI 6 or HLö 7. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852700/),min,7,247910,DB00747,Scopolamine
,8852700,Maximal plasma concentration,"Maximal plasma concentration was 33 ng ml-1, elimination half-life 52 min, Vapp 3.2 l kg-1 and Clpl 44 ml min-1 kg-1.",Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet combination autoinjectors containing HI 6 or HLö 7. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852700/),[ng] / [ml],33,247911,DB00747,Scopolamine
,8852700,elimination half-life,"Maximal plasma concentration was 33 ng ml-1, elimination half-life 52 min, Vapp 3.2 l kg-1 and Clpl 44 ml min-1 kg-1.",Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet combination autoinjectors containing HI 6 or HLö 7. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852700/),min,52,247912,DB00747,Scopolamine
,8852700,Vapp,"Maximal plasma concentration was 33 ng ml-1, elimination half-life 52 min, Vapp 3.2 l kg-1 and Clpl 44 ml min-1 kg-1.",Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet combination autoinjectors containing HI 6 or HLö 7. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852700/),[l] / [kg],3.2,247913,DB00747,Scopolamine
,8852700,Clpl,"Maximal plasma concentration was 33 ng ml-1, elimination half-life 52 min, Vapp 3.2 l kg-1 and Clpl 44 ml min-1 kg-1.",Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet combination autoinjectors containing HI 6 or HLö 7. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852700/),[ml] / [kg·min],44,247914,DB00747,Scopolamine
,1269215,volume of central compartment,"Mean (+/- SE) pharmacokinetic parameters were: volume of central compartment, 0.09 +/- 0.03 L/kg; total apparent volume of distribution, 1.02 +/- 0.09 L/kg; distribution T 1/2, 0.90 +/- 0.09 min; apparent elimination T 1/2, 137 +/- 14 min; total clearance, 378 +/- 63 ml/min.",Kinetics of high-dose intravenous morphine in cardiac surgery patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269215/),[l] / [kg],0.09,250461,DB00747,Scopolamine
,1269215,total apparent volume of distribution,"Mean (+/- SE) pharmacokinetic parameters were: volume of central compartment, 0.09 +/- 0.03 L/kg; total apparent volume of distribution, 1.02 +/- 0.09 L/kg; distribution T 1/2, 0.90 +/- 0.09 min; apparent elimination T 1/2, 137 +/- 14 min; total clearance, 378 +/- 63 ml/min.",Kinetics of high-dose intravenous morphine in cardiac surgery patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269215/),[l] / [kg],1.02,250462,DB00747,Scopolamine
,1269215,distribution T 1/2,"Mean (+/- SE) pharmacokinetic parameters were: volume of central compartment, 0.09 +/- 0.03 L/kg; total apparent volume of distribution, 1.02 +/- 0.09 L/kg; distribution T 1/2, 0.90 +/- 0.09 min; apparent elimination T 1/2, 137 +/- 14 min; total clearance, 378 +/- 63 ml/min.",Kinetics of high-dose intravenous morphine in cardiac surgery patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269215/),min,0.90,250463,DB00747,Scopolamine
,1269215,apparent elimination T 1/2,"Mean (+/- SE) pharmacokinetic parameters were: volume of central compartment, 0.09 +/- 0.03 L/kg; total apparent volume of distribution, 1.02 +/- 0.09 L/kg; distribution T 1/2, 0.90 +/- 0.09 min; apparent elimination T 1/2, 137 +/- 14 min; total clearance, 378 +/- 63 ml/min.",Kinetics of high-dose intravenous morphine in cardiac surgery patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269215/),min,137,250464,DB00747,Scopolamine
,1269215,total clearance,"Mean (+/- SE) pharmacokinetic parameters were: volume of central compartment, 0.09 +/- 0.03 L/kg; total apparent volume of distribution, 1.02 +/- 0.09 L/kg; distribution T 1/2, 0.90 +/- 0.09 min; apparent elimination T 1/2, 137 +/- 14 min; total clearance, 378 +/- 63 ml/min.",Kinetics of high-dose intravenous morphine in cardiac surgery patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269215/),[ml] / [min],378,250465,DB00747,Scopolamine
,11711265,T(max),"The T(max) of ceftizoxime (CTIZ), the active moiety of AS-924, was slightly prolonged by scopolamine butylbromide (T(max)=1.8 vs. 1.5 h for the group without pretreatment).","Effects of gastrointestinal stimulant and suppressant pretreatment on the pharmacokinetics of AS-924, a novel ester-type cephem antibiotic. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711265/),h,1.8,256398,DB00747,Scopolamine
,11711265,T(max),"The T(max) of ceftizoxime (CTIZ), the active moiety of AS-924, was slightly prolonged by scopolamine butylbromide (T(max)=1.8 vs. 1.5 h for the group without pretreatment).","Effects of gastrointestinal stimulant and suppressant pretreatment on the pharmacokinetics of AS-924, a novel ester-type cephem antibiotic. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11711265/),h,1.5,256399,DB00747,Scopolamine
,14747425,AUC(0-4h),"As expected for a drug excreted predominantly in unchanged form by the kidneys, tiotropium plasma concentrations increased as renal impairment worsened, with mean values of 55.5 (16.2 percent geometric coefficient of variation [%gCV]), 77.1 (20.1 %gCV), 101 (29.8 %gCV), and 108 (27.3 %gCV) pgh/mL for AUC(0-4h) in the normal renal function and the mild, moderate, and severe renal impairment groups, respectively.","Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14747425/),[pgh] / [ml],55.5,257356,DB00747,Scopolamine
,14747425,AUC(0-4h),"As expected for a drug excreted predominantly in unchanged form by the kidneys, tiotropium plasma concentrations increased as renal impairment worsened, with mean values of 55.5 (16.2 percent geometric coefficient of variation [%gCV]), 77.1 (20.1 %gCV), 101 (29.8 %gCV), and 108 (27.3 %gCV) pgh/mL for AUC(0-4h) in the normal renal function and the mild, moderate, and severe renal impairment groups, respectively.","Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14747425/),[pgh] / [ml],77.1,257357,DB00747,Scopolamine
,14747425,AUC(0-4h),"As expected for a drug excreted predominantly in unchanged form by the kidneys, tiotropium plasma concentrations increased as renal impairment worsened, with mean values of 55.5 (16.2 percent geometric coefficient of variation [%gCV]), 77.1 (20.1 %gCV), 101 (29.8 %gCV), and 108 (27.3 %gCV) pgh/mL for AUC(0-4h) in the normal renal function and the mild, moderate, and severe renal impairment groups, respectively.","Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14747425/),[pgh] / [ml],101,257358,DB00747,Scopolamine
,14747425,AUC(0-4h),"As expected for a drug excreted predominantly in unchanged form by the kidneys, tiotropium plasma concentrations increased as renal impairment worsened, with mean values of 55.5 (16.2 percent geometric coefficient of variation [%gCV]), 77.1 (20.1 %gCV), 101 (29.8 %gCV), and 108 (27.3 %gCV) pgh/mL for AUC(0-4h) in the normal renal function and the mild, moderate, and severe renal impairment groups, respectively.","Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14747425/),[pgh] / [ml],108,257359,DB00747,Scopolamine
,23819698,FEV1,"Overall, 414 patients were randomized and treated (FEV1 1.63 L [55.8% predicted]).","Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23819698/),l,1.63,262323,DB00747,Scopolamine
,23819698,AUC0-24,"Compared with placebo, FEV1 AUC0-24 and FEV1 AUC12-24 were significantly increased from baseline with aclidinium (∆ = 150 mL and 160 mL, respectively; p < 0.0001) and tiotropium (∆ = 140 mL and 123 mL, respectively; p < 0.0001) at week 6.","Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23819698/),ml,150,262324,DB00747,Scopolamine
,23819698,AUC0-24,"Compared with placebo, FEV1 AUC0-24 and FEV1 AUC12-24 were significantly increased from baseline with aclidinium (∆ = 150 mL and 160 mL, respectively; p < 0.0001) and tiotropium (∆ = 140 mL and 123 mL, respectively; p < 0.0001) at week 6.","Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23819698/),ml,140,262325,DB00747,Scopolamine
,23819698,AUC12-24,"Compared with placebo, FEV1 AUC0-24 and FEV1 AUC12-24 were significantly increased from baseline with aclidinium (∆ = 150 mL and 160 mL, respectively; p < 0.0001) and tiotropium (∆ = 140 mL and 123 mL, respectively; p < 0.0001) at week 6.","Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23819698/),ml,150,262326,DB00747,Scopolamine
,23819698,AUC12-24,"Compared with placebo, FEV1 AUC0-24 and FEV1 AUC12-24 were significantly increased from baseline with aclidinium (∆ = 150 mL and 160 mL, respectively; p < 0.0001) and tiotropium (∆ = 140 mL and 123 mL, respectively; p < 0.0001) at week 6.","Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23819698/),ml,160,262327,DB00747,Scopolamine
,23819698,AUC12-24,"Compared with placebo, FEV1 AUC0-24 and FEV1 AUC12-24 were significantly increased from baseline with aclidinium (∆ = 150 mL and 160 mL, respectively; p < 0.0001) and tiotropium (∆ = 140 mL and 123 mL, respectively; p < 0.0001) at week 6.","Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23819698/),ml,140,262328,DB00747,Scopolamine
,23819698,∆,"Compared with placebo, FEV1 AUC0-24 and FEV1 AUC12-24 were significantly increased from baseline with aclidinium (∆ = 150 mL and 160 mL, respectively; p < 0.0001) and tiotropium (∆ = 140 mL and 123 mL, respectively; p < 0.0001) at week 6.","Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23819698/),ml,160,262329,DB00747,Scopolamine
,16175141,releasing rate,The patch releases 0.5 mg alkaloid over a period of 3 days (releasing rate 5 microg/h).,Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175141/),[μg] / [h],5,263383,DB00747,Scopolamine
,16175141,Peak plasma concentrations (Cmax),Peak plasma concentrations (Cmax) of approximately 100 pg/mL (range 11-240 pg/mL) of the alkaloid are reached after about 8 hours and achieve steady state.,Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175141/),[pg] / [ml],100,263384,DB00747,Scopolamine
,16175141,tmax,"When scopolamine was administered together with 150 mL grapefruit juice, the alkaloid concentrations continued to increase, resulting in an evident prolongation of tmax (59.5 +/- 25.0 minutes; P < 0.001).",Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175141/),min,59.5,263385,DB00747,Scopolamine
,16175141,absolute bioavailabilities,"Consequently, the related absolute bioavailabilities (range 6% to 37%) were significantly higher than the corresponding values of the drug orally administered together with water (range 3% to 27%).",Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175141/),%,6,263386,DB00747,Scopolamine
,16175141,absolute bioavailabilities,"Consequently, the related absolute bioavailabilities (range 6% to 37%) were significantly higher than the corresponding values of the drug orally administered together with water (range 3% to 27%).",Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175141/),%,37,263387,DB00747,Scopolamine
,16175141,absolute bioavailabilities,"Consequently, the related absolute bioavailabilities (range 6% to 37%) were significantly higher than the corresponding values of the drug orally administered together with water (range 3% to 27%).",Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175141/),%,3,263388,DB00747,Scopolamine
,16175141,absolute bioavailabilities,"Consequently, the related absolute bioavailabilities (range 6% to 37%) were significantly higher than the corresponding values of the drug orally administered together with water (range 3% to 27%).",Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175141/),%,27,263389,DB00747,Scopolamine
,22542656,IC(50),ASP2535 potently inhibited rat GlyT1 (IC(50)=92 nM) with 50-fold selectivity over rat glycine transporter-2 (GlyT2).,"A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22542656/),nM,92,265111,DB00747,Scopolamine
,22542656,IC(50),It showed minimal affinity for many other receptors except for μ-opioid receptors (IC(50)=1.83 μM).,"A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22542656/),μM,1.83,265112,DB00747,Scopolamine
>,24928173,duration of,"In vitro, aclidinium, glycopyrronium and tiotropium had a long duration of action at native M3 receptors (>8 h versus 42 min for ipratropium).",The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24928173/),h,8,268623,DB00747,Scopolamine
,24928173,duration of,"In vitro, aclidinium, glycopyrronium and tiotropium had a long duration of action at native M3 receptors (>8 h versus 42 min for ipratropium).",The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24928173/),min,42,268624,DB00747,Scopolamine
,24928173,time to 50% recovery of effect [t½ offset],"Aclidinium had a longer duration of action than glycopyronnium (time to 50% recovery of effect [t½ offset] = 29 h and 13 h, respectively); these compare with a t½ offset of 64 h and 8 h for tiotropium and ipratropium, respectively.",The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24928173/),h,29,268625,DB00747,Scopolamine
,24928173,time to 50% recovery of effect [t½ offset],"Aclidinium had a longer duration of action than glycopyronnium (time to 50% recovery of effect [t½ offset] = 29 h and 13 h, respectively); these compare with a t½ offset of 64 h and 8 h for tiotropium and ipratropium, respectively.",The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24928173/),h,13,268626,DB00747,Scopolamine
,24928173,t½ offset,"Aclidinium had a longer duration of action than glycopyronnium (time to 50% recovery of effect [t½ offset] = 29 h and 13 h, respectively); these compare with a t½ offset of 64 h and 8 h for tiotropium and ipratropium, respectively.",The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24928173/),h,64,268627,DB00747,Scopolamine
,24928173,t½ offset,"Aclidinium had a longer duration of action than glycopyronnium (time to 50% recovery of effect [t½ offset] = 29 h and 13 h, respectively); these compare with a t½ offset of 64 h and 8 h for tiotropium and ipratropium, respectively.",The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24928173/),h,8,268628,DB00747,Scopolamine
,24928173,dose required to produce half-maximal effect [ED50],"Aclidinium was less potent than glycopyrronium and tiotropium at inhibiting salivation in conscious rats (dose required to produce half-maximal effect [ED50] = 38, 0.74 and 0.88 μg/kg, respectively) and was more rapidly hydrolysed in rat, guinea pig and human plasma compared with glycopyrronium or tiotropium.",The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24928173/),[μg] / [kg],38,268629,DB00747,Scopolamine
,24928173,dose required to produce half-maximal effect [ED50],"Aclidinium was less potent than glycopyrronium and tiotropium at inhibiting salivation in conscious rats (dose required to produce half-maximal effect [ED50] = 38, 0.74 and 0.88 μg/kg, respectively) and was more rapidly hydrolysed in rat, guinea pig and human plasma compared with glycopyrronium or tiotropium.",The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24928173/),[μg] / [kg],0.74,268630,DB00747,Scopolamine
,24928173,dose required to produce half-maximal effect [ED50],"Aclidinium was less potent than glycopyrronium and tiotropium at inhibiting salivation in conscious rats (dose required to produce half-maximal effect [ED50] = 38, 0.74 and 0.88 μg/kg, respectively) and was more rapidly hydrolysed in rat, guinea pig and human plasma compared with glycopyrronium or tiotropium.",The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24928173/),[μg] / [kg],0.88,268631,DB00747,Scopolamine
